Speculation Stocks ... https://swingtradebot.com/equities/most-tracked There isn't a day that goes by on Wall Street when certain stocks trading for under $10 a share don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline and solid risk management are banking ridiculous coin on a regular basis. Roberto Pedone... Street.com http://moxreports.com/
They took a company with essentially no business operations and little revenue and deceived the market and their clients into believing it was worth hundreds of millions of dollars through a dizzying round of unauthorized trades and deceptive promotions. In the end, the deceived investors were left holding the empty bag,”
Some RULES for this I-Hub Board........... This board will be used for analysis of charts ranging in different time periods to determine signals for trading of various instruments=individual stocks, etf's and options. Please direct your comments towards technical indicators that everyone can see on a price chart: we are talking about signals and technical indicators here, not opinions or predictions or forecasts of when the next grand slam will be... share technical signals and charts with the group and if you have an active position...... Rather than being opinionated and letting your subjective bias determine which side of the market to be on, try to maintain objectivity based on technical analysis.
One of the key items to remember as investors/traders is that the market doesn't always reflect reality. Oftentimes it reflects belief. And belief can prove to be a delusion. "A belief held without objective examples that everyone can see is a delusion." “Opinion is that exercise of the human will which 'lets' us make a decision without objective information and objective examples.” And is obviously ....not the best choice that promotes a healthy process. “Discussion is an exchange of knowledge; an argument an exchange of ignorance.” Understand the above and you will understand the phrase..."Self will run riot" and you can expect the results of this riot will be destructive for yourself first and then for others.
Dysfunctional attitudes and behaviors = "self will run riot" it is not a process that builds "character". It is not common decency, nor any form of kindness...it can only be destructive. It is no disgrace to be wrong... disgrace happens when you choose to stay wrong... Anticipation vs. Rewards: Is it in the Stock or in the Brain? Life's Lessons Lesson #1 – The cover up is often worse than the original problem. Don’t expect them to admit it. Strategy #1: “The best way to expose a liar is to just let them keep talking”. Strategy #2: “Make sure to give the guilty party enough rope to hang themselves”. Building character is a project you never complete.
We form our character in defining moments because we commit to irreversible courses of action that shape our personal and professional identities. We reveal something new about us to ourselves and others because defining moments uncover something that had been hidden or crystallize something that had been only partially known. And we test ourselves because we discover whether we will live up to our personal ideals or only pay them lip service. YES Symphonic...And You and I If you feel you must GAMBLE and encourage gambling from the 5 minute or lower time frames you will be asked to take your message to the "gamblers board"...If you feel you "must offer an opinion or off topic comment; please do it after trading hours. Charts and signals at signal lines is what we want...and If you feel you do not need to answer questions on this board ...then why are you here.
I-Hub's rules state: It is the burden of each poster to ensure that their posts do not contain content that qualifies them for removal. It doesn't matter if your post contains the cure to the common cold or the best stock tip since (fill in your favorite ticker here), if it contains other content that is a violation of the site's rules of conduct, then it qualifies for removal. ...
Thank You... Kiy...ki...theMatrix You are only as good as your next trade...Kiy This release may contain "forward-looking statements" that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as "may", "will", "aim", "will likely result", "believe", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "project", "should", "will pursue" and similar expressions or variations of such expressions. ...
********************************************************************************************************************************************************************************************** Most investors are steady, careful people who seek out the best possible advice before they act.
They spend a lot of time trying to understand the investment environment, and have a good sense of the risks associated with any given trade
Then there are the gamblers. Most of them are also pretty clear about the risks associated with their decisions. Like any good gambler, they take risks — calculated risks.
Then there are the desperate. They are driven by a sense of panic … by the need to make a big score, perhaps to make up for years of financial neglect.
A high proportion of those desperate folks are attracted to cryptocurrencies. (https://banyanhill.com/dont-get-burned-cryptocurrencies/)
The S&P500 Index, one of many indicator of stock market performance (by tracking big US businesses), averaged 9.5% annual returns from 1928 to 2015
Now let’s take our $5 a day, which adds up to to $1,825 a year, and put it into an S&P500 or total stock market index or mutual fund. Which just means it should have similar performance, over the long term, as the S&P500’s 9.5% annual returns. We contribute this $5 a day in weekly or monthly chunks (this is important).
You start to accrue both the money you contributed, that $5 a day, and the 9.5% a year returns. Then those contributions and the returns, plus the second year’s contributions, earn another 9.5%. And so on and so fourth. This won’t be the exact case for the year 1 and year 2, because the stock market is SUPER unpredictable in the short term. But in the long term, you can expect decent returns.
After 25 years, we can reach over $180,000 dollars. Your contributions of $5 a day, only make up 1/4 of that total sum. 75% of that is JUST EARNINGS.
After 35 years, we can reach half a million dollars. Can you spare $5 a day for a $500,000 payday? 87% of that is purely earnings!
Henry David Thoreau famously stated in Walden that “the mass of men lead lives of quiet desperation.” He thinks misplaced value is the cause: We feel a void in ourlives, and we attempt to fill it with things like money, possessions, and accolades.
Regression to the Mean is the most powerful law in financial physics Mean reversions out of extremes are the most powerful and profitable forces in all the financial markets. Riding one has enormous benefits for your wealth. Financial-market prices and sentiment are like a giant pendulum. The farther they are pulled to one extreme by excessive greed or fear, the farther they necessarily swing to the opposite extreme in the subsequent mean reversion. Like pendulums, these reversions don’t magically stop right in the middle at normal again. Their kinetic momentum carries them through to the opposite ends of their arcs. But overshoot extremes don’t last for long, as the universal greed necessary to fuel them quickly burns itself out. Markets are not about beliefs, but about sentiment. And, if you can track sentiment, If you can measure sentiment... then you are in a position to make your investment account grow without the need for excuses. (...this really is all you need to know about the Markets; ...
Brutal Truth About Today’s World
The Sad Truth About Today’s World Illustrated By Steve Cutts
Art isn’t all fairytale photoshoots and landscape shots – it can also act as catalyst of change. And Steve Cutts thinks that many things in the world should be different. Work shouldn’t be a grinding, soul-crushing rat race for the almighty dollar. Consumerism shouldn’t hold a vice-like grip on our lives. And social media, well, we need to throw-off the shackles we so eagerly put on ourselves. Wouldn’t life be better then?
Wish You Were Here ...Comfortably Numb .... Hey You
.... Brain Damage "There's someone in my head, but its not me"...(Recall what was said about ego) ..... Us and Them....
WE Are Borg...you will be assimilated...
Elon Musk and AI experts urge U.N. to ban artificial intelligence in weapons
Earlier this year, Elon Musk unveiled details about his new venture Neuralink, a California company that plans to develop a device that can be implanted into the brain and help people who have certain brain injuries, such as strokes. The device would enable a person’s brain to connect wirelessly with the cloud, as well as with computers and with other brains that have the implant.
The end goal of the device, Musk said, is to fight potentially dangerous applications of artificial intelligence.
“We’re going to have the choice of either being left behind and being effectively useless or like a pet — you know, like a house cat or something — or eventually figuring out some way to be symbiotic and merge with AI,” Musk said in a story on the website Wait But Why.
Always trade with the direction of the daily CCI
Swing trades= Always trade in the direction of the daily bias even for short term trades...if you really feel you must trade against the daily bias...you need a hair trigger...get out quick if the position moves against you. The Average True Range for SPX usually runs around 15 points. This range inceases as volatility increases
Remember...What you're looking at on an intraday chart is a daily candle or OHLC price bar "uncompressed" from the daily chart. Kind of a "micro" view of the Macro daily chart...and daily would be a micro view of the weekly chart...
Front Running a Daily chart signal (...The 60 minute chart can be considered as a proxy for the daily chart and will lead daily chart signals when daily CCI is getting ready to come out of oversold overbought levels...it just takes patience to get the timing..) This way; rather than only trade the intraday cycle you can use the intraday charts to front run a daily CCI signal. When the Daily CCI is ready to move out of oversold or overbought... your goal eventually is to catch a trade from intraday that carries over onto the daily chart. It just takes some practice and patience becoming comfortable with the CCI cycles= Intraday/Daily/Weekly and as the 3cycles sometimes line up together= synchronized you may consider a larger position. Best trades will be trades that are trading in the same direction as the daily chart's bias...=Commodity Channel Index CCI 20 points the way...
There is a "Method to the Madness of Crowds" and you can find it and define it on the charts...Technical Charting takes away some of the fear/doubt in trading... and then all you need is patience while waiting for the chart to tell you when the bias/momentum/sentiment turns...listen to signals at signal lines(simple enough...yes?...)...Kiy...
The Market is a giant feedback loop, showing traders (and anyone who views the market) a thermometer reading of the social mood under which traders, and by extension society, are operating. Most traders seem to think of the market as something that has some external value outside of the price attributed to it by traders. I prefer to think of it as a real-time gauge of a society’s view of their own productive capacity…or more simply put–social mood. When Markets are understood, the idea that everyone can make money is not only inaccurate but impossible and laughable. Everyone making money means there is no market, because who would be willing to take the other side of the trade? In addition, most traders feel they can move with the crowd to make a (paper) profit, and then get out before the crowd, turning that trade into a real profit. In theory this is sound, but remember everyone else is setting out to do the same thing. It is this crowd movement which allows traders to make money at times. Without a large portion of traders coming to the same decision markets simply would not move. It takes conviction by many traders to create a trend, then it takes euphoric acceptance that “this is the new norm” to end it and “bend it. ” It then takes mass disillusionment to crash it the other way. (vantagepointtrading.com)
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- https://scan.alpaca.ai/symbol/SLV/ http://www.stockta.com/ http://www.buyupside.com/sample_portfolios/lithium.php
FDA Calender https://www.tipranks.com/stocks/fcx
Price Target https://finbox.io/fcx
fair value https://stocknews.com/stock/fcx/ https://swingtradebot.com/equities/FCX https://www.google.com/finance?q=FCX&ei=6p84WZm8E9aMjAHSlLTYDg Fair Value (fv) estimates are from https://financhill.com/search/valuation/GG http://oracledispatch.com/ http://wealthyventurecapitalist.com/ www.insidercow.com Color Code of stock symbols/letters....MVIS (T/$3.50H-4.50) example MVIS letter colors indicate the stock price is pointing down and all the letters are boxed in with green= oversold oversold MVIS=MVIS and you should be looking/considering a long position...(T/$3.50H-4.50) and someone has put a $4.50 price target on it. (..."T"=target price...the "H" indicates the first target price has been hit... Colors are based on reading the CCI 20 (Commodity Channel Index signal lines) ... if "letters" are colored =Green =UP...Red=down...lighter colors = less confident in direction...if letters/stock symbols are Boxed in=Green =oversold=anticipate an "UP" cycle for the CCI 20 indicator or a mean reversion price bounces = at least to centerline within the Bollinger Bands 20,2= the 20 day moving average... and if the box is red=Red=overbought=anticipate a "DOWN" cycle... §=Reverse of a Signal line(focus is the technical indicator CCI centerline...overbought line +100 and oversold line -100)... ¥= first stock to turn UP/Down after the Group/Sector has been overbought/oversold. Stocks that have a "Target" price are the better choice for a trade...example...MVIS (T/$3.50H-4.50) a target price with an "H" behind it says the target was "hit" since the target price was added...here MVIS has a second target price of $4.50...so if you find MVIS oversold you can consider a long position if you are comfortable with the width of the Bollinger Bands and the target price will give you 10% or more profit... remember this; PRICE= %B and CCI they indicate very much the same and they represent price within the parameters of the Bollinger Bands (box Price inside the Bollinger Bands. The %B tends to lead the CCI signals (a little)... A few of the more interesting ETFs/Sectors http://www.direxioninvestments.com/products/direxion-daily-sp-500-bull-3x-etf?gclid=CPPB6bX5-s0CFRSUfgodGfQGMA ...Candle Glance Charts= click on the ETF's symbol and you'll get a set of the largest holdings 10-12 stocks in that ETF. FINANCIAL Rising bond yields are good for financials like banks and insurers, but are bad for bond proxies like utilities (and REITs). 03/15... The Fed hiked rates today as expected, with expectations for two more hikes this year. Judging from immediate market reactions, the Fed announcement is being viewed as somewhat dovish. For one thing, bond yields are dropping. With yields falling, bond prices are having a strong day. Junk bonds, which have been correcting lately, are especially strong. That's also positive for stocks. Rate sensitive stock groups like utilities and REITs are leading a strong market response. Falling yields, however, are weighing on bank stocks. The dollar is also dropping. XLF CandleGlance (15.3%)BRK.B,*JPM,WFC, ***BAC (T/$24H-26),C,SPG,USB,CB,*AIG,*GS, ....................................... ZPAS ...PUMP AND DUMP...?....OR DISRUPTIVE... https://www.fidelity.com/sector-investing/information-technology/overview XLK CandleXGlance AAPL,MSFT,FB,T,GOOGL,GOOG,VZ,V,INTC,CSCO .............. ***HDP (T/$21) ... SGH (T/$21H) ...QBAK .........TECZ ...1xBear ...REW ...2xBear... TECS ...3xBear SMH CandleGlance Semiconductor ...AMD,MVDA,CY,IDTI,IPHI,MPWR,MU,MXIM,TXN,LLTC http://www.buyupside.com/sample_portfolios/semiconductorsmems.php ...INTC (T/$40)...AMD (T/$11H-17-22) ... MRAM (T/$19H)... ....¥*****RESN (T/$8)...... ICHR (T/$25).. COHU (T/$25) ... CY (T/$14H-18) ... AMSC (T/$11)
SSG.short Semiconductor... ASYS
(T/$8H-12) equip... SCON HACK Cyber Security... IMPV,BLOX,PANW,QLYS,JNPR,SAIC,FTNT,CSCO,SYMC,CHKP.........***CYBR(T/$55),FEYE,TMICF,PFPT,AVG... SNSR CandleGlance Global Internet Of Things...SWKS,MBLY,GRMN,ST,BRCD,DXCM,JCI,SLAB,BDC,IDCC,ADI ... OTIV (T/$2.25)... MX (T/$13) ..............................NDCVF...SWIR...PTC...ARW...SFE... Global Internet Of Things According to researchers, the global market for IoT in 2020 is going to be worth $373 billion in terms of sales. Hardware will account for 52% of sales — devices ranging from personal wearable technology to smart homes to connected cars. The remaining 48% will pour in from the software and analytics required to turn the copious amounts of data generated by hardware into usable information. Leading market research firm IDC forecasts China to spend $128 billion on IoT by 2020. India’s spending will come in around $10 billion to $12 billion by 2020. And forecast sales for the Middle East and Africa are at $11 billion by 2019. .****IOTS (T/$5H-7H-10) ultra low power (flash) memory., trademark resistive RAM technology called Conductive Bridging RAM (CBRAM®). CBRAM® is a breakthrough technology platform that enables 100 times less energy consumption than today’s flash memory technologies as well as delivering enhanced performance. Visit: http://www.adestotech.com PRNT 3D Printing 3D Printing Jan 2017 International Data Corporation (IDC) Worldwide Semi-Annual 3D Printing Spending guide is predicting that the rapid expansion of the 3D printing industry is expected to continue without slowing down. According to the IDC analysts, global revenues for the 3D printing market will explode to a massive $35.4 billion by the year 2020. With 2016 revenues expected to reach $15.9 billion which means the industry could nearly double within the next five years. http://www.marketwired.com/press-release/3dx-industries-metal-printing-division-positioned-for-assertive-growth-in-2017-otcqb-dddx-2189898.htm http://www.buyupside.com/sample_portfolios/3dprinters.php DDD 3D Systems (T/$13-25), SSYS.(T/$24H-33) Stratasys .. XONE (T/$11)..ExOne... ¥ VJET (T/$6) Voxeljet ... ......................................MTLS Materialise Sftwre... DDDX 3D Ind ... HPQ sftwre IYZ Telecom... T,VZ,TMUS,CLT,SBAC,LVLT,S,FTR,SHEN ....TDS....(WIN ... RNG... QTNA (T/$24-28) SONS (T/$10)... SHOR (T/$10) PXQ Networking... QCOM,APH,AAPL,CHKP,CSCO,VMW,CA,CTXS,FNSR,BLOX ...GIMA,LOGM,... SSNI (T/$11H-14)Smart Grid... ...............SONS (T/$8.50) Sonus Networks, Inc. (Sonus) is a provider of networked solutions for communications service providers and enterprises to help them secure and unify their real-time communications infrastructures. Company helps communications service providers and enterprises hold the session initiation protocol (SIP) and fourth generation (4G)/long term evolution (LTE)-based solutions, including voice over Internet protocol (VoIP), voice over wireless fidelity (VoWiFi), video and unified communications (UC) by securing and enabling Internet Protocol (IP) networks. Its products include session border controllers (SBCs), diameter signaling controllers (DSCs) and VoWiFi solutions. Sonus Products include Sonus GSX9000 Open Services Switch, Sonus T7000 Intelligent Switching System, Sonus Diameter Signaling Controllers, Sonus Signal Transfer Points, Sonus PSX Policy & Routing Server, Sonus WebRTC Services Solution, Sonus Network Management Solutions and Virtualized Mobile Core (VMC) Solution. GEX Global Alt. Energy...TSLA,VWSYF,ETN,GAM,ENS,FSLR,CREE,ITRI,ORA,POWI,CVA,...CLPXF,NDRBF,KTWIF,NIBE B ICLN Global Clean Energy...CLPXF,OEZVF,CVA,CHFFF,VWSYF, PHO Water Resources WAT,ROP,ECL,DHR,HDS,IEX,TTC,AOS,RXN,AWK,VMI...TTEK,WTR, CGW Global Water Index... AWK,DHR,XYL,IEX....... (CDZI...Water Utility) TAN ...FSLR,SCTY,GCPEF,TERP,TSL,SPWR,CAFD,ABY ... RUN (T/11) ... VSLR (T/$6h)... SUNW (T/$2.50)
................................................ ENPH (T/$1) Enphase’s new IQ microinverters
.....................................................***** WNDW Disruptor and upstart ...HAS VOLUMESolarWindow Technologies, Inc. has developed transparent electricity generating coatings that can go onto any glass surface, such as windows or sunroofs. Imagine a Tesla being able to top off its batteries while on the road. And since these coatings generate electricity under natural, low and even shaded light conditions, that Tesla could be charging up all day. The solar cell is no longer the dominant cost of the energy it produces. The majority of the cost increasingly lies in everything else—the inverter, installation labor, permitting fees
.....----------------------------------------------------------------------------------------------------------------------- The inflation pipeline has three stages. The first stage is the price of raw materials. The second stage is the price companies pay for raw materials (producer price inflation). The third stage is what companies charge consumers for their products (CPI inflation). It all starts with the direction of commodity prices. Strangely, that's the part that economists (and the Fed) pay no attention to. How can economists expect to predict the final stage of CPI inflation, if they ignore the first stage which is the direction of commodity prices? ...John Murphy StockCharts.com
Watch...cobalt goes in lithium batteries... ECSIF eCobalt Solutions... Cobalt metal --------------------------------------------------------------------------------
“Promoted stocks tend to rise because of the work of the stock promoter. But, later on, usually share price declines when the promo dollars dry up. Thus, buyers beware! The share price could keep creeping up as more emails are sent out and new market participants buy shares. Some will make money. However, in a few days, weeks or months, the stock promotion will stop or the exchange will warn the market about it, and the share price may fall sharply.
Just be careful... Pumps & Dumps 101
This is your brain on stocks
5 Brain Flaws that make you a lousy investor
*****Virtual Reality/Augmented Reality/Artificial Intelligence In the real world, Artifical Intelligence9(AI) will enter our lives in three phases and forms:
Portfolio of Artificial Intelligence (AI) Chip Stocks --- Portfolio of Artificial Intelligence (AI) Stocks
PHASE #1 Assisted Intelligence: AI that replaces repetitive and mundane tasks traditionally done by humans
. A timely example would be the proliferation of robots used at Amazon to “pick” items from warehouse shelves, which we mentioned in last month’s issue. You’ll recall we’re already double-digit gains in the space (with more to come) in the Robo Global Robotics & Automation ETF (ROBO)
and Cognex Corp. (CGNX).
PHASE #2 Augmented Intelligence: AI that incorporates machine learning to supplement and support human analysis. One area where this type of AI is being implemented is legal discovery. That is, the period of time in which both legal parties gather evidence. Seventy-five percent of the costs associated with discovery are tied to human review of documents. And people are expensive. Using AI to pre-screen — and reduce the amount of relevant documents before humans even start reviewing the files — can dramatically reduce costs. We profited from this very technology when our portfolio position Epiq Systems was acquired for a 40% gain in July 2016.
PHASE #3 Autonomous Intelligence: AI that takes over for humans in a highly specific task. Self-driving cars would be the ultimate example of this in action.
AI appears on our smartphones, with personal assistants, augmented and virtual reality headsets, robots, in data centers, and in semi and fully autonomous vehicles.
AI will be dominated by the big names such as Apple, Amazon, Alphabet Google, Facebook, and Samsung; however some smaller names like Nvidia and AMD can also do well.
AI will be invisible, yet it will be everywhere. https://seekingalpha.com/article/4086169-look-artificial-intelligence-companies-top-5 AMD (T/$8H-20) Advanced Micro Devicesis a semiconductor manufacturer. The company's new AI chips are the Radeon Instinct series. AMD is also racing to put its chips into AI applications. AMD will release its ROCm deep-learning framework, as well as an open-source GPU-accelerated library called MIOpen. The company plans to launch three products under the new brand in 2017. ***08/04
AI = "machines with brains"
https://www.thestreet.com/story/14256965/1/amd-falls-in-premarket-as-abu-dhabi-s-sells-part-of-stake.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo Abu Dhabi is largest share holder after recent sells still owns 13% of outstanding shares... Softbank (OTC:SFBTF)(they bought out chip designer ARM, and own 4.95% of Nvidia)
AAOI started 2017 with monthly production of lasers which go into the multiplexer or transceiver modules at a rate of 300 per month. They announced production will ramp to 1 million per month by year end. In the first quarter 2017 average production was 400,000 per month. May 2017 production was up to 600,000 per month, 50% above 1Q2017. AAOI has the highest margins of all the competition. Positive cash flow. Lowest cost structure with plants in Texas, Taiwan and China.
- Applied Optoelectronics Inc. (NASDAQ:AAOI) - Design and manufacture high speed data and fiber-optic network products, such as transmitters and receivers. 2017 PE is 14.2, and 2018 PE is 12.6 representing excellent value for a growth stock. Analyst consensus price target is US$75.78, representing 23% upside.
It is no secret that Automotive makers are racing each other to mass produce the first autonomous car. To achieve fully autonomous driving, cars need to have a variety of sensors to perceive near and far fields of visions in every direction. The sensors include radar, LIDAR, ultrasonic, cameras, and night vision devices. The data collected by these sensors are fed into highly complex System on Chips (SoCs) with compute performance that is equivalent to what only supercomputers could deliver a few years ago. Complex, state of the art algorithms that are increasingly based upon artificial intelligence ensure vehicle, driver, passenger, and pedestrian safety based on factors such as traffic, weather, dangerous conditions, etc https://www.micron.com/solutions/automotive Next level memory is an integral part of AI. I recommend you getting up to speed on the demands we're talking about in memory today. this is not about storage capacity. this is about on demand, real time access to data that has to solve a problem immediately. This is the next level of memory that only 2 or 3 companies can do. It's a workload solution not just a storage solution. think about a car that needs to calculate what is happening around it immediately. thats not a storage solution, thats a storage plus speed and cross referenced access in real time. only 3 or 4 companies in the world have this capability and innovation, and Micron is one of the only american ones. This is why Nvidia and Intel are partnered with Micron. here is a great discussion about it:http://bit.ly/2tSxWWi
- Fabrinet (NYSE:FN) - Design and manufacture transceivers, transponders, optical amplifiers, lasers, and sensors. 2017 PE is 13.7, and 2018 PE is 12.2 representing excellent value for a growth stock. Analyst consensus price target is US$52.55, representing 23% upside.
Others in this sector which are more telco focused include NeoPhotonics (NYSE:NPTN), Oclaro (NASDAQ:OCLR), Finisar (NASDAQ:FNSR), and Lumentum (NASDAQ:LITE).
MU, memory based processing is the future.
02/28/17 ...potential profits in the VR/AR industry are enormous. Goldman Sachs (GS) estimates that the market will reach $80 billion by 2025, with the potential for that figure to actually soar much higher, to more than $180 billion.
Many of the companies developing VR/AR hardware and software are among the biggest names in Silicon Valley including Apple (AAPL), Alphabet (GOOG), Amazon (AMZN), Facebook (FB) and Sony (SNE). Autoliv ALV
On a July 26, 2016 conference call with analysts, AAPL's CEO Cook said he was bullish about augmented reality. "AR can be really great, and we have been and continue to invest a lot in this," Cook said. "We are high on AR for the long run. We think there are great things for customers and a great commercial opportunity." In September, Cook told ABC News
that augmented reality presented a bigger business opportunity than virtual reality. "There's virtual reality and there's augmented reality — both of these are incredibly interesting," Cook said. "But my own view is that augmented reality is the larger of the two, probably by far."
Augmented reality superimposes digital images in a person's field of vision. It provides the user with information for navigation, to complete tasks and other purposes. By contrast, virtual reality is an immersive media that places the wearer of special headsets into a completely digital world, mostly for entertainment purposes. In November, Bloomberg reported that Apple had already ordered "small quantities of near-eye displays from one supplier for testing." It said Apple was in the exploration phase of wearable computing. The device being tested would connect wirelessly to the iPhone. Also in November, KGI analyst Ming-Chi Kuo said Apple is looking to leapfrog the competition in AR by three to five years with its offering. But Kuo said it could take Apple one to two years to come out with an AR product.
....Sony Facebook's Oculus virtual reality device Samsung, Microsoft Hololens...Google Glass
Head worn devices...ZBRA Zebra Technology... INTC Intel...FJTSY Fujitsu...
Sales of virtual reality and augmented reality headsets will surge by 2021, when 100 million a year of the devices may be sold, according to a new report by research firm IDC.
Zion Market Research forecasts that the global AR market will grow at an annual pace of 85% until 2021, hitting a size of $134 billion.
HIMX (T/$6H (H=hit $6 target)next T/$10H now T/$12) Himax Technologies 07/14 Oppenheimer downgrades Himax Technologies from Perform to Underperform with a $4 price target= Sept 8th“Our business and strategic initiatives remain on track,” said Jordan Wu, President and CEO of Himax. “We have publicly presented management’s view on our businesses including display driver IC segment and 3D sensing opportunities with very consistent messages to the investment community. We also recently announced 3D sensing total kopn
solution on August 30, 2017. We remain optimistic in our leading position in the 3D sensing supply chain, and have strong confidence that we will achieve the deliverables on the existing and new growth opportunities.” The Company would like to caution investors that the Oppenheimer analyst has not spoken to the company in the past four months despite multiple offers. The Company disagrees with the analyst's view on our business prospects and his statements regarding the Company’s position within the 3D sensing supply chain.....hyped as the I-PHONE KILLER (I really don't know why...here's a why=3D cameras...semicndtr, display driver integrated circuits (ICs), timing controllers used in televisions (TVs), laptops, monitors, mobile phones, tablets, digital cameras, car navigation, et al...The company is ramping up for more sales of its liquid crystals on silicon (LCOS) and wafer-level optics (WLO) products for AR devices after ramping up production for both later this year and into 2018. Himax says that the ramp-up is because its AR customers are looking to their next generation devices, and that Himax's tech will benefit from that. (buy after 2nd quarter 2017...) you may want to wait even longer... Himax management is talking about having a lot of smartphone customers coming in and requesting support for WLO, but the talk needs to translate into revenue growth later in the year. For now, the company's guidance doesn't match management's optimism: The midpoint of its second-quarter revenue guidance indicates that Himax's top line will drop almost 25% year over year. Analysts aren't too optimistic about Himax's performance, either, as they project a 17% revenue decline for fiscal 2017, which will lead to a weak earnings performance. At the same time, Himax is quite expensive, at 36 times last year's earnings, way higher than its 13-year median price-to-earnings ratio of 17. What's even more surprising is that Himax shares could become more expensive in the next year. Wall Street projects a forward P/E ratio of 48, thanks to a potential drop in earnings.Investors, therefore, should adopt a wait-and-see approach despite the hoopla around AR technology. Himax shares seem to have run up too fast this year, driven by rumors and speculations, not by any concrete financial gains. https://www.fool.com/investing/2017/07/12/will-himax-technologies-augmented-reality-bet-pay.aspx
*****KOPN (T/$3.70H-5) Kopin Corporation semvis
micndtr...wearable technologies and display products...develops, makes and markets virtual and augmented reality gaming, training, and simulation products. Kopin’s Whisper™ Voice Chip, Solos™ smart glasses and Pupil LCD display modules will be among the Kopin products displayed on the CES show floor.
Kopin has transitioned to a wearable-centric company - they have positioned themselves to be entirely levered to success in Enterprise and Consumer head-worn AR with components and licensable IP.
When you combine high level AR market forecasts with Kopin's device share dominance with design wins inside 5 Industrial AR headsets, I believe it is clear this stock is the one to own if you are looking to lever your portfolio to the massive growth possible in the head-worn wearable segment.
As I have noted previously and pointed out in my blog posting "The Wearables Acquisition Intel Needs To Make - And Fast!" I believe a current reasonable market capitalization value for Kopin would be $394M or north of $5.00/share based on the following: https://seekingalpha.com/article/4070837-small-private-company-disrupting-industrial-ar-market
"The Wearables Acquisition Intel Needs To Make - And Fast!" I believe a current reasonable market capitalization value for Kopin would be $394M or north of $5.00/share based on the following:
- IP portfolio I have valued at at least $300M: Kopin holds over 300 granted & pending wearables patents; I believe they possess the strongest head-worn wearables IP portfolio in the industry
(T/$16H-20) LG Display MVIS (T/$3.00H-4.50) Microvision makes PicoP scanning technology for three-dimensional sensing and image capture. IMMR (T/$8H-13) Immersion Corporation...the creation of the sense of touch to the user through the use of vibrations or motions. Immersion is one of the leaders in this technology, also known as kinesthetic communication. (very weak guidance for all of 2017) *****OCLR (T/$11H-15-21) lasers and optical components partner with CEIN...Oclaro provides differentiated solutions for optical networks and high-speed interconnects driving the next wave of streaming video, cloud computing, application virtualization and other bandwidth-intensive and high-speed applications....The Company provides various solutions for optical networks and interconnects driving the next wave of streaming video, cloud computing, application virtualization and other bandwidth-intensive and high-speed applications. The Company's product offerings include client side transceivers, line side transceivers, tunable laser transmitters, lithium niobate modulators, transponder modules, and discrete lasers and receivers. It designs, manufactures and markets optical components, modules and subsystems that generate, detect, combine and separate light signals in optical communications networks. The Company supplies transmission products at the component level and the module level into 10 gigabits per second (Gb/s), 40 Gb/s and 100 Gb/s communications solutions. The Internet is a massive network of networks. Every one of those networks is dependent on data-transferring devices such as routers and switches connecting to wires and connecting to each other. A growing number of these networks connect to fiber to move data faster. But you need freakin' laser beams to move data on fiber, and that makes it difficult to connect routers and switches that are transmitting data with fiber, so ... Acacia Communications (ACIA) simplifies the process by taking data from lasers and moving it between devices using standard silicon chips. And those chips can work with virtually any form of optical networking equipment and also plug into existing networks that aren't designed to transmit data with laser beams. (Motley Fool) NPTN§ (T/$13-17) NeoPhotonics high speed digital optical signals... FN ...*FNSR (T/42) ... SIGM
(T/$8) Sigma Designs, Inc. provides integrated system-on-chip (SoC) solutions and intelligent platforms for use in various home entertainment and home control appliances. ***EMAN (T/$4) light emitting diode (OLED) on silicon micro displays; virtual imaging products that utilize OLED micro displays; and related products. It offers super video graphics array (SVGA) + OLED micro displays; digital SVGA OLED-XL; super extended graphics array OLED-XL and OLED-XL/XLS; video graphics array OLED-XL; widescreen ultra-extended graphics array OLED-XL; and WF05 prism optic with mounting brackets or combined with OLED micro displays to form an optic-display module. The company also provides design reference kits, which include a micro display and associated electronics to help original equipment manufacturers (OEMs) evaluate micro display products; near-eye virtual imaging modules that incorporate its OLED-on-silicon micro displays with its lenses and electronic interfaces for integration into OEM products; immersive head mounted display products; and night vision smartphone camera attachment and goggles. It serves OEMs in the military, industrial, medical, and consumer market sectors. ***** VUZI (T/$11) VUZI smart glasses ... ****NEON
(T/$3.50) touch screen and ability to sense an object's size,deph,velocity, pressure, proximitty to any type surface....
SYNA ...ACIA... AAOI... LITE (T/45H) ... BBRY
(T/$13-15) BlackBerry..."When Wall Street shifts its frame of expectations toward the future, and gets over their legacy business, watch out." The company has high expectations for BlackBerry's QNX secure industrial operating system and future sales. QNX is a self-driving car software and so far, has been installed in already more than 60 million cars. Ford's Sync 3 infotainment system runs on it as well as Audi's TT virtual cockpit. According to the Citron report, BlackBerry's QNX far exceeds the 16 million units that Mobileye has installed, a rival autonomous vehicle tech company that Intel Corp said it would purchase for $15.3 billion. INTC (T$38-42) (fv$41.80)..Buying as of03/13 =Mobileye...*MBLY Triple Digit Stock develops computer vision/machine learning/data analysis/localization/mapping for advanced driver assistance systems and autonomous driving technologies primarily in Israel.
... Mobileye...We believe the stock’s reaction to the Tesla news was an overreaction
because 1) Tesla comprises about only 1% of Mobileye’s revenue today 2) Mobileye said that of its $1.1BN 2019 revenue target, Tesla contributes ~2% (or ~$17MM on 350K cars).” Anderson sets a $60 price target; the stock is rebounding, up $2, or 4.4%, at $47.33. Anderson writes that his own digging suggests the split had been in the works for some time, and that graphics chip maker Nvidia (NVDA
is likely being tapped by Tesla to produce an alternative: Our sense from talking with industry sources is that the relationship between Mobileye and Tesla has been headed to this outcome for some time. We believe Tesla would like to push the envelope more with autonomous features and increasingly with their own algorithms. Our best guess at this point (based on our checks) is that Tesla will eventually migrate to a hardware solution from Bosch with processing done by Nvidia using internally-generated Tesla algorithms.
Intel (NASDAQ:INTC) has been very active acquiring companies involved in the burgeoning wearable technology segment. You will find a great overview from Matt Margolis in his article entitled, "Intel Is Quietly Emerging As The Augmented Reality World Leader." Despite this acquisition activity, there are still significant gaps if Intel wants to repeat the "Intel Inside" strategy for wearables that it so successfully employed in the PC era.
In my opinion, these are the missing pieces from Intel's current wearables ecosystem:
- Proven high yield micro display and complementary optical technology
Next generation noise cancellation hardware and software
Head-worn reference designs - the new Intel Inside motherboard!
Licensable user interface IP covering voice and gesture input methods
Software middleware or a wearables operating system
Broad wearables patent protection
Interestingly, there is a way for Intel to achieve gap closure in all of the areas above with a single transaction: they could acquire Kopin Corp. (NASDAQ:KOPN).
Assuming Intel is as interested as I think they should be, what would this transaction look like and how can we benefit?
General Motors announced it will begin offering unlimited data for owners for just $20 per month. That’s a steal, considering rates for in-car data started at about $500 for 30 gigabytes in 2014. Considering the average person spends 42 hours per year in traffic — and upward of 80 hours in major metropolitan areas — the car represents the next battleground for media and telecom companies. In short, there’s a lot of revenue up for grabs — over $80 billion by 2021. The sooner companies can get consumers to start connecting in the car, the more market share they stand to capture. Bottom line: Price is always a barrier to adoption. But GM just eliminated it. ...5G networks promise to offer 10–100 times faster data speeds and lower latency. Our recommendation of PCTEL stands to benefit as initial rollouts begin, since it sells equipment vital to testing new wireless networks. However, 5G network progression also bodes favorably for our investments in the internet of things, virtual personal assistants, connected cars and associative computing. Faster processing speeds make these technologies more compelling. That includes Memex Inc. (OEE:TSX-V), Control4 Corp. (CTRL), GSI Technology Inc. (GSIT) and Visteon (VC). So keep buying https://agorafinancial.com/2017/03/18/prepare-yourself-for-the-invisible-technology-revolution/?pdf=1 VSH ...(T/$15H-16.25H) Vishay Intertechnology ...broadens its optoelectronics portfolio with the introduction of a new high speed silicon PIN photodiode with enhanced sensitivity for visible light. Vishay Semiconductors VEMD5080X01 offers fast switching times and low capacitance for precise signal detection in wearable devices and medical, industrial, and automotive applications. *ISNS ... Image Sensing Systems, Inc. develops and markets software-based computer enabled detection products and solutions for the intelligent transportation systems industry. Its video and radar processing products are used in traffic, security, police, parking applications, such as intersection control, highway, bridge, tunnel traffic management, venue security, entry control, LPR, traffic data collection. *****NVDA (T/145H-200) Nvidia neural imprinting and all forms of virtual reality... http://traderprep.com/2016/08/04/4-automakers-betting-on-nvidia/ ...Tesla’s co-founder and CEO, Elon Musk, has promoted NVIDIA’s GPUs as a key element for driverless car technology. At the 2015 GPU Technology Conference last year, Musk said that what NVIDIA is doing with its Tegra GPU’s will prove “really important for self-driving in the future.” While Tesla uses NVIDIA’s GPUs, it doesn’t currently use NVIDIA’s Drive PX system, though there’s no reason why it couldn’t in the future. Why all of this matters for NVIDIA investors NVIDIA’s self-driving car focus is becoming increasingly important because of the technology’s quick adoption by both automakers and consumers. IHS Automotive estimates that between now and 2035, there will be 76 million vehicles on the road with some level of self-driving capabilities. Cheaper technology is spurring growth, as is evidenced by Honda’s $20,040 Civic, which can drive itself on the highway. The driverless-car market is expected to grow to $42 billion by 2025, according to Boston Consulting Group, and it’s clear that NVIDIA’s mapping out a plan to grab as much of that market as possible with its current automotive partnerships.
PCTEL Inc. (PCTI) and Visteon Corp. (VC). http://www.buyupside.com/sample_portfolios/mobilegames.php VOICE
... the iPhone kicked off what can affectionately be dubbed the “Touchscreen Era.” But the sun is setting on that period. We’re now entering the “Smart Voice Era.” And once again, it’s being pioneered by Apple and its introduction of a virtual assistant in 2011. Very soon, the days of pulling your smartphone from your pocket... swiping to unlock it… opening an app… and then tapping what you want will seem burdensome. Instead, just speak your desire into the air — anywhere — and it will be done. Thanks to key advances in artificial intelligence, voice interfaces can now learn in real-time, enabling them to accomplish an ever-increasing number of difficult and nuanced tasks.
companies like Nvidia and GSI Technology Inc. (GSIT) are at the forefront of this development. ******GSIT
(T/$9H) Remember how Nvidia leveraged the benefits of “parallel processing” to net windfall sales and profits for investors in 2016? Well, GSI’s in-place associative computing chips will leverage “massive parallel processing” capabilities. ****Think Nvidia on steroids.***SO WHERE ARE THE STERIODS ...?...
Key Tasks Currently Accomplished by Voice Assistants ? Check Or Add an Item to Calendar ? Place an Online Order ? Send a Hands-Free Text ? Set an Alarm ? Conduct an Internet Search ? Read the News ? Get a Weather Forecast ? Play a Song ? Control Smart Home Devices (Thermostat, Lighting, etc.) ? Get a Traffic Update ? Check Spelling ? Call an Uber ? Add Something to a To-Do List ****DSPG
(T/$15) DSP Group Inc. (DSPG) is a leading provider of digital signal processing chips. Its core knowhow is enabling better voice communications. HDClear solution. It’s a comprehensive noise-suppression and voice quality-enhancement chipset for mobile devices. HDClear incorporates the company’s proprietary noise-cancellation algorithms to deliver unrivaled voice quality in any situation. And it does so using very low power, which is a key consideration for device makers. Simply put, HDClear enables voice interfaces to hear clearly and process commands efficiently. No matter how noisy the environment. Management estimates there are currently over 2 billion potential devices that could benefit from its HDClear chipset. And they’re not wasting any time capturing that upside potential. Case in point: New product sales increased 48% in 2016. And they’re headed higher still, as DSP secured two design wins in the voice interface market. These will enter mass production in the second half of 2017. With over 30 years of voice processing expertise — and 227 patents and applications — we couldn’t ask for a better-positioned company to benefit from the rapid transition to voice interfaces. A Rapidly Growing and High-Probability Pipeline: DSP’s new engagement pipeline for HDClear covers voice-enabled products in every product category — IoT, smart assistants, PCs, wearables, smart speakers, home appliances and automotive.
As management said, “We are excited with the market dynamics and the greenfield opportunity in the voice activation and control space.” Given DSP’s technology leadership, it’s only a matter of time before these opportunities are converted into design wins. But don’t just take my word for it. As management confirmed, “We actually feel a lot more bullish about our ability to penetrate and get design wins in this market.” Naturally, more design wins will lead to steadily increasing sales — and, in turn, profits. Speaking of which… New Products Already Driving Growth and Margin Expansion: After debuting with gross margins in the high 30% range, last quarter they increased to 56.6%. Higher margins lead to higher profits, which ultimately leads to higher share prices. https://agorafinancial.com/2017/03/18/prepare-yourself-for-the-invisible-technology-revolution/?pdf=1 *****HEAR
(T/$1.90) 4D sound...
(T/$3.50-4) xG Technology
a leading provider of wireless video solutions to broadcast, law enforcement and defense markets, and private mobile broadband networks for critical communications. "The recent acquisitions of Vislink and IMT position XGTI to lead the market for wireless video broadcasting systems, in our view. We expect an approximately 10-year, $2.0 billion hardware up-fit opportunity as a result of a recent spectrum auction to drive accelerated growth in 2019, and as the market share leader, XGTI is positioned to benefit." In addition, "We expect share gains in the company’s satellite communications business to be a key growth driver." Other Tech Stocks AMBA (T/$84)... Ambarella produces systems on a chip for various camera applications such as GoPro action cams and drones. These chips incorporate numerous patented technologies that allow them to work with very low power, in low ambient light conditions, and with highly efficient compression capabilities. *CPST Capstone Turbine... microturbine...
GLNNF () GlancePay MEET (T/$6) SOCIAL NETWORK...
*****WATT WATT Energous...wire-free charging of electronic devices at a distance...
***PRCP (T/$11) Perception Inc... 3D scanning products, laser scanners ...
As for the iPhone 8, one of the main rumors
so far is related to the inclusion of wireless charging technology in the phone. Wireless charging is an interesting concept, and current options rely on magnetic energy to charge, requiring users to place their device on some sort of compatible pad. Energous Corporation WATT, an innovative wireless charging company that uses RF waves to charge. Energous promises “long-distance” wireless charging, and many people think the company could be teaming up with Apple to incorporate the tech in the iPhone 8. (http://finance.yahoo.com/news/iphone-8-rumors-apple-long-194407615.html
) MU Micron is the third largest mobile DRAM and fourth largest NAND manufacturer in the world. It's arguably the most straightforward play on the memory-chip market for investors, Samsung Electronics (NASDAQOTH:SSNLF), and Western Digital (NASDAQ:WDC) icron is currently developing next-gen memory technologies such as 3D NAND and 3DXPoint with Intel (NASDAQ:INTC), Radio Frequency Identification (RFID) isn't just a gamble. It's real, and the stakes are high. Identifying worthy players in disruptive technologies. Motley Fool ROP ...Roper Technologies ... Roper makes a wide array of products including water meters, energy pump testers, and medical imaging equipment. Roper makes RFID equipment used at tollbooths to facilitate the reading of prepaid express passes. This is naturally a booming market. The days of bypassing tolls are long gone as cars are scanned through tollbooths, and the fact that RFID technology requires fewer tollbooth operators is gravy to controlling costs. ZBRA Zebra Technologies (NASDAQ:ZBRA) -- Using RFID to track inventory is made easier through Zebra's solutions. It offers mobile and handheld readers as well as fixed readers. It also makes reader antennas to send data across various points of business activity. Zebra is also a leading distributor of RFID printers that allow businesses to encode and print out the RFID-backed labels that can be tracked with its readers. GPIC Gaming Partners (NASDAQ:GPIC) -- The company makes gaming equipment, and that included at the time a thriving business embedding RFID microchips in casino chips to facilitate immediate inventory tallies and prevent counterfeit currency. It continues to offer RFID readers for cage, table, and vault applications as well as RFID technologies for casino readers. RFID isn't just a gamble. It's real, and the stakes are high. Identifying worthy players in disruptive technologies ALAN AVGO AVY AWSL BDX CKP CYRP DOW IDSY IIJI MANH OPRX ORCL PG PHG QRVO RVP SCSC SKVY SPCB STM TSEM SWKSTXN TYC VRSN WMT ZBRA Semi/Cloud/Biometrics ... ***ADI... Biometrics, drones..semicondtrs ****ANY () tech. cloud, storage...July 11 did a 1 for 25 reverse split CNIT..Internet service company that provides cloud-based platform China... ****SFUN (T/$9) Chinese real estate Internet portal CUDA (T/$25h-29) Barracuda ... cloud-enabled solutions that enable customers to address security threats, improve network performance, and protect and store their data. It provides various security solutions, including Barracuda Email Security (01/09 earns/profit beat) EIGI (T/$10.50)...cloud ***FTR (T/$)telecom fiber-to-the-home and cloud backup, sharing, identy protection... *GSB* () software cloud based ...
****HIVE (T/$9-10) cloud-managed mobile platform... INVE (T/$10) Identiv, Inc. operates as a security technology company that secures and manages access to physical places, things, and information worldwide. It operates through four segments: Premises (PACS), Identity, Credentials, and All Other. The PACS segment offers modular Hirsch MX controllers that allow customers to start with a small system and expand over time; Hirsch Velocity software platform for centralized management of access and security operations across an organization; Federal Identity, Credential and Access Management architecture, an access control system; and TouchSecure door readers that provide various features to support security standards. The Identity segment provides smart card readers, which include various contact, contactless, portable, and mobile smart card readers, as well as tokens and terminals to enable logical access, and security and identification applications, such as national ID, payment, e-health, and e-government. It also offers access cards and other devices related to its reader products. The Credentials segment provides NFC and radio frequency identification products, including inlays and inlay-based, and other cards; and labels, tags, and stickers, as well as other radio frequency and integrated circuits components for use in various applications, such as virtual reality, games, loyalty cards, mobile payment systems, transit and event ticketing, and brand authenticity from pharmaceuticals to consumer goods, hospital resource management, cold-chain management, and others. MODN (T/$16) ...provides revenue management cloud solutions for the life science and technology industries *NXTD (T-$4) biometrics security mobile devices, electronic wallet virtually any magnetic stripe card allow single electronic card to replicate cards for MobileBio VoiceMatch ...http://finance.yahoo.com/news/nxt-id-inc-demonstrates-module-130000868.html ***PSTG (T/13H-15) Provides flash memory-based enterprise storage hardware... ****STM (T/$14H-$20) STMicroelectronics Semicndctr ****USAT (T/$6) wireless networking, cashless transactions, asset monitoring... BioMetrics biometrics (fingerprint, retinal, voice and facial recognition) stocks --- http://www.buyupside.com/sample_portfolios/biometrics.php AWRE (T/$5.50) Aware software products are used in government and commercial biometrics systems to identify or authenticate people. It offers biometrics software products, including biometric services platform, search and match products, software development kits, and application products for fingerprint, facial, and iris modalities that enable various functions in biometrics systems, such as enrollment, analysis, and processing of biometrics images and data on workstations or mobile devices; integration of peripheral biometric capture devices; centralized workflow, transaction processing, and subsystem integration; matching of biometric samples against biometric databases to authenticate or verify identities; and analysis and processing of text-based identity data. BKYI (T/$5.50) BIO-KEY...fingerprint biometric identification and identity verification technologies, cryptographic authentication-transaction security technologies, as well as related identity management and credentialing software solutions. The Company is also engaged in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, identity cards, public key infrastructure (PKI), credit card, passports, driver's licenses, one-time password (OTP) or other form of possession or knowledge-based credentialing. Its solutions identify individuals and verify, or confirm, their identity before granting access to, among other things, corporate resources, subscribed data and services, Web portals, applications, physical locations or assets.
IWSY ImageWare Systems...biometrically enabled software-based identity management ... *NXTD (T-$4) biometrics security mobile devices, electronic wallet virtually any magnetic stripe card allow single electronic card to replicate cards for MobileBio VoiceMatch ...http://finance.yahoo.com/news/nxt-id-inc-demonstrates-module-130000868.html SMME () Smart Metric PI (T/$40H) Impinj ...radio frequency ID chip-maker, maker of RAIN RFID chips Portfolio of Airport Security Stocks Portfolio of Cyber Security Stocks Portfolio of Security Stocks Portfolio of Video Surveillance Stocks
****BOTZ...Global Robotics and Artificial Intelligence.. ISRG 7.9%, MBLY 4.8%,TRMB5.4%,IRBT,BRKS,FARO ROBO CandleGlance Global Robotics&Automation...KYCCF,CYBQF,YASKF,CGNX,ISRG, OMRNF,FARO,DAIUF, NCTKF,YASKF,RAVN, FANUF,KRNNF,DAIUF,ROCK,ABLZF,NCTKF,AVAV,AMANF,ARAY,HOLI,JNPKF,BRKS .... GOSY Robot...CareBOT...
........ RWLK (T/$3.00-4.00) Robotics exoskeleton ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. www.rewalk.com ... MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, June 12, 2017 /PRNewswire/ -- ReWalk Robotics Ltd. (RWLK) ("ReWalk"), leading manufacturer of exoskeleton systems, today announced a Florida court ruling that found Blue Cross Blue Shield of Florida must provide coverage of a ReWalk exoskeleton system for a plan member with a spinal cord injury ("SCI"). This court decision is the latest of several in the United States that have ruled in favor of the individual after original denial of claims by commercial insurers. EK EKSO (T/$4) Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company's Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation to develop products for military applications, as well as with OttoBock Healthcare Products Gmbh.
GLOBAL MEDICAL ROBOTICS is expected to reach USD 20.56 billion by 2022 from USD 6.36 billion in 2016 at a CAGR of 21.6% during the forecast period. Neurology segment is expected to register the fastest growth during the forecast period. This growth is attributed to the advent of newer applications in neurosurgery and the growing popularity of robotic neurosurgery. http://crweworld.com/newsroom/prnewswire?rkey=20170915IO82767&filter=10284
A medical robot is the one which is used by surgeons for greater access to areas under operation using more detailed and less invasive methods. They are in most telemanipulators, which use the surgeon's actions on one side and to control the "effector" on the other side. The medical robotic systems market is majorly fuelled by the enhancement of automation technologies, the rising incidence of disabilities in human beings and rising baby boomer population, that impede their day-to-day physical motions. North America has the highest market share of the medical robotics market in 2016. Its large share is attributed to the high adoption rate of medical robots in the region and the government's strong focus on medical robots to improve the quality of healthcare. Asia Pacific medical robotic systems market is expected to grow at the fastest rate during the forecast period due presence of untapped market/opportunities. Key factors that drive the demand for medical robots market include rapidly growing demand for precise and efficient minimally invasive surgeries. Growth in the volume of these surgeries, as a consequence of growing disease prevalence levels is also likely to drive the market growth. However, the high cost of surgery, negative publicity, and wariness among people continue to challenge the growth. Medical nanotechnology is employing nanorobots that when injected into the patient work at a cellular level. Instruments & Accessories Robotic Systems Surgical Robots Laparoscopy Surgical Robotic Systems Orthopedic Surgical Robotic Systems Neurosurgical Robotic Systems Steerable Robotic Catheters Rehabilitation Robots Therapeutic RobotsAssistive Robots Prosthetics Orthotics Exoskeletons Non-invasive Radiosurgery Robots Hospital and Pharmacy Robots Pharmacy Robots\ IV Robots Telemedicine Robots...
Companies: Intuitive Surgical, Inc. Stryker corporation Accuray, Inc Hansen Medical, Inc. Mazor Robotics IRobot Corporation ReWalk Robotics Siemens Healthcare Aurora Biomed MAKO Surgical Corp. Abbot Diagnostics ZOLL Medical Corp Agilent Technologies Baxter International Roche Holding Kirby Lester Biotek Instruments Carefusion Aesynt Inc Hocoma AG...
***TRXC (T/$2.75) ...TransEnterix ... focuses on the development and commercialization of surgical robotic systems. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port, robotically enhanced laparoscopic surgical platform. In addition, the company develops and manufactures flexible and rigid laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. WEAR wearable technologies/components IRTC,DXCM,BSX,AAPL,GGNDF,BEAT,KN,TASR,PODD,ABT http://www.buyupside.com/sample_portfolios/wearables.php wearable devices that will ship this year to enterprise customers from public companies including Fujitsu (OTCPK:FJTSY), Vuzix (NASDAQ:VUZI), Google (NASDAQ:GOOG), and Intel (NASDAQ:INTC). Market estimates vary widely, but a recent report by Grand View Research estimates the enterprise wearables market will be valued at more than $20B by 2025. SKYY CandleGlance ETF Cloud Computing ...AKAM,ORCL,EQIX,NTAP,AMZN,CSCO,OTEX,JNPR,FB ... *****VERI (T/$13H-17H-19) ...Veritone, Inc., a cloud-based cognitive software company, develops a proprietary artificial intelligence platform for various markets in the United States and internationally. Its cloud-based open platform integrates and orchestrates an ecosystem of cognitive engines to reveal multivariate insights from various amounts of audio, video, and structured data; and incorporates proprietary technology to manage and integrate a range of AI processes to mimic human cognitive functions comprising perception, reasoning, prediction, and problem solving to transform unstructured data into structured data. The company offers media agency services, including media planning and strategy, media buying and placement, campaign messaging, clearance verification and attribution, and custom analytics to manage, deliver, optimize, verify, and quantify advertising campaigns and content distribution for various clients across multiple channels comprising broadcast radio, satellite audio, streaming audio, broadcast and cable television, digital video, and podcasting. It also provides Software-as-a-Service solutions for media owners and broadcasters to automatically index and organize audio and video content to search, discover, and analyze their media for programming and optimization; political organizations to analyze public and private media, conduct research, and provide access to previously inaccessible data; legal professionals to find the critical details of their cases by storing, organizing, and analyzing evidentiary media; and police and other government authorities to organize and gain insight from the large amount of audio, video, and structured data they accumulate on a daily basis, as well as offers solutions for other markets, including commercial security and retail. Veritone® Inc. (NASDAQ:VERI), a leading provider of artificial intelligence (AI) based solutions, announced today that they have introduced extensive language translation support for virtually any type of media, including audio and video files, emails and text documents, within Relativity®, kCura’s e-discovery software that helps organizations worldwide manage and analyze large volumes of unstructured data. With the Veritone Media Player, Relativity users can now employ machine translation for over 100 languages, including Chinese, French, German, Italian, Japanese, Russian and Spanish, for evidentiary media. The Veritone Media Player also now incorporates Relativity’s Structured and Conceptual Analytics for expedited and efficient discovery of content and key topics. Initially integrated into the Relativity Ecosystem at the beginning of 2017, Veritone unlocks the power of AI-based cognitive computing, enabling unstructured evidentiary media such as audio and video files to be processed, transformed, and analyzed to generate truly actionable intelligence. The platform can render every second and frame of audio and video content searchable for things like words, phrases, faces, sentiment, and voice identification. Veritone now also provides machine translation, in addition to its existing redaction and transcription capabilities, to produce an index of the processed data within minutes – a process that as recently as 2015 could take thousands of hours. “With Relativity, we deliver an easy and convenient solution that both accelerates and increases the capabilities of the eDiscovery process, generating actionable information from data that was previously inaccessible,” said Mike McDonald, senior vice president of Veritone Legal. “The improvements to the early case assessment and e-discovery processes alone are impressive, but what’s truly valuable is the impact this technology will have on the legal industry and its potential to influence trials, evidentiary use and case outcomes.”
****CISN (T/$16) Cision Ltd. provides public relations (PR) software, media distribution, media intelligence, and related professional services worldwide. It offers Cision Communications Cloud, an earned media cloud-based platform that brands can use to build relationships with influencers and buyers in order to amplify their marketplace influence; and provides media database that offers access to influencers when planning a campaign, as well as to schedule and record various interactions with contacts DTRM (T/$3) Determine... the company offers Determine Cloud Platform, an open technology infrastructure for application in strategic sourcing, supplier management, contract lifecycle management, procure to pay, business, analytics, business network, and configuration solutions. It also provides SmartContracts, a solution that streamlines contract processes from request, authoring, negotiation, approval, and e-signature through ongoing obligations management, analysis, reporting, and renewals; SmartSource, an enterprise scale solution to support the processes of supplier on-boarding, supplier selection, and on-going supplier management; and SmartAnalytics, which delivers business insights and executive reporting. In addition, the company offers Configuration Solution, a patented configuration engine, which streamlines the management and dissemination of product information, enabling companies to streamline the opportunity-to-order process for manufacturers, service providers, and financial services companies. OOMA (T/$10.50-12)... Smart office, Smart homes..., Cloud platform Ooma creates new communications experiences for small businesses and consumers. Its smart platform serves as a communicationthe Ooma Telo – the system includes motion, water, door and window sensors in addition to the unique ability to remotely place a local 911 call from the home, thus providing all-encompassing protection s hub, which offers cloud-based telephony, internet security, home security and other connected services. Ooma combines PureVoice HD call quality and innovative features with mobile applications for reliable anytime, anywhere calling. The company has been ranked the No. 1 home phone service for overall satisfaction and value for five consecutive years by the leading consumer research publication. added to the Russell 2000® and Russell 3000® Indexes ****TNTR (T/$9-16) Tintri, Inc. develops and markets an enterprise cloud platform combining cloud management software technology and a range of all-flash storage systems for virtualized and cloud environments in the United States and internationally. Its platform provides large organizations and cloud service providers with public cloud capabilities inside their data centers and public cloud services. The company addresses a range of cases, including development operations, disaster recovery and data protection, server virtualization, and desktop virtualization. It also offers its products related support, installation, and training services. Organizations use Tintri all-flash storage with scale-out and automation as a foundation for their own clouds—to build agile development environments for cloud native applications and to run mission critical enterprise applications. Tintri enables users to guarantee the performance of their applications, automate common IT tasks to reduce operating expenses, troubleshoot across their infrastructure, and predict an organization’s needs to scale—the underpinnings of a modern data center. That’s why leading cloud service providers and enterprises, including Comcast, Chevron, NASA, Toyota, United Healthcare and 21 of the Fortune 100 companies trust Tintri with enterprise cloud.. http://finviz.com/quote.ashx?t=TNTR&ty=c&ta=1&p=d YEXT (T/$14H-18) 4 Brookers like this... IPAS... ...............................
............................................................................................................................................................................................................................................................................................................................................. BIO/Pharma/Medical ...
President Donald Trump has stated on multiple occasions that he plans to eliminate restrictions on drug development for the FDA. This policy would positively affect biomedical companies, as their products would reach the open market more easily and frequently. Certain biomedical companies will pose a stronger investment as the FDA revises their drug development standards.
With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year.
terminology...you master the terminology and then you can master the subject...
A reasonable price-to-sales ratio for biotechs is 4.0 (MF) According to the FDA, around 30% of drugs that make it to late-stage studies win approval. FDA had granted Breakthrough Therapy designation. The status allows for promising drug candidates to undergo expedited development and review processes from regulators, sometimes even based on mid-stage trial results. European Medicines Agency (EMA) and Committee for Medicinal Products for Human Use (CHMP) Prescription Drug User Fee Act (PDUFA) goal date adult growth hormone deficiency (AGHD) Epinephrine Pre-filled Syringe “PFS," EpiPen PAD peripheral artery disease Pulmonary Hypertension (PH-COPD). “Pulmonary Hypertension with IPF or COPD Biotech Stocks - I
--- Biotech Stocks - II
--- Biotech Stocks - III
--- Biotech Stocks - IV
--- Biotech Stocks - V Portfolio of Big Pharmaceutical Stocks: Cancer Portfolio of Big Pharmaceuticals Stocks: Arthritis Portfolio of Big Pharmaceuticals Stocks: Diabetes ****ACHN (T/$6-10)...Achillion Pharm ... *****ADMP (T/$10)...June FDA APPROVAL HAPPENED=http://www.investopedia.com/investing/betting-adamis-pharmaceuticals-and-ocular-therapeutix-ahead-fda-decisions-admp-ocul/?partner=YahooSA&yptr=yahoo Adamis has a vision for its Epinephrine Pre-filled Syringe “PFS," which is designed as a cost- ***AGRX (T/$10) Women's contrception...weekly patch approvedalternative for those suffering from anaphylactic reactions. The drug maker hopes to compete with the likes of Mylan's EpiPen that has been raking in billions. Late last year, generic pharmaceuticals giant, Mylan (NASDAQ:MYL) found itself caught in the crosshairs of a nationwide controversy involving steep increases in the pricing of its life-saving drug injector, EpiPen. Since 2009, the price of an EpiPen two-pack has risen from $100 to over $600 today. These results have been great for Mylan's financials, as last year, EpiPen was responsible for approximately $1 billion in revenue and accounted for 40% of Mylan's total operating profits. But it has been a public relations nightmare. On the backs of this controversy, Mylan reacted by announcing that the company would be launching a generic version of the EpiPen late last year. This generic version would be priced at half the cost of the branded EpiPen -- around $300. Even so, at half the sales, this would still be a $500 million indication. And one tiny biotech is chomping at the bit in its efforts to dethrone Mylan's EpiPen empire. With the FDA's decision expected on June 15, Maxim analyst Jason Kolbert seems to not be concerned by the Complete Response Letter the company received from the regulator last year. While the FDA expressed concerns and pushed the firm to work on expansion of the human factors study, Adamis has since handled these challenges successfully. The expansion was just a "low hurdle" to the analyst, as he does not see this to be a meaningful roadblock in any way to Adamis' success. The analyst is also excited about the market opportunity the company is pursuing, noting, "We see a billion dollar market, and in Adamis PFS a superior product [...] If Adamis can acquire just 10% market share and generate sales approaching $100M (which we believe is the low end), it suggests shares are undervalued." Ultimately, Kolbert believes Adamis' valuation is compelling. As such, the analyst reiterates a Buy rating on Adamis shares, with a $10.00 price target, which implies 185% potential upside from current level ADRO
(T/$18) Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the company's products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. Dec 30FDA AEZS (T/2H -4 for 2018) AEterna FDA has accepted the drug maker's New Drug Application (NDA) for Macrilen (macimorelin), a novel orally-active ghrelin agonist intended to help in monitoring treatment for adult growth hormone deficiency (AGHD) ***AGRX (T/$10) SHARE DILUTION Aug. 3rd 5.33 million shares at $3.75 ...Women's contrception...weekly patch December 26, 2017 as the Prescription Drug User Fee Act (PDUFA) goal date.
ALDR () ...Alder Biopharmaceuticals... A wave of new preventive migraine medications are on the horizon.The migraine market is huge. An estimated 38 million Americans have migraines — and Dr. Eric Pearlman, a medical fellow at Lilly, one of the companies developing these treatments, told Business Insider that about 15 million of those migraine sufferers would be eligible for preventive treatment. Alder Biopharmaceuticals, eptinezumab which would be administered on a quarterly basis, is in phase 3 trials. The company plans to submit to the FDA in the second half of 2018.****08/11 ADMA (T/$13) ADMA Biologics plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia.
ALIM (T/$3-5) Alimera Sciences... The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
AKTX (T/$6) Akari Therapeutics... focuses on therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barre syndrome, and atypical hemolytic uremic syndrome.
AMAG (T/$20h-34) “Severe preeclampsia can be a life-threatening condition and is a contributing factor in a significant number of preterm births in the U.S., yet no FDA-approved treatment options currently exist,” said Julie Krop, M.D., chief medical officer and senior vice president, clinical development and regulatory affairs at AMAG. “The development and potential approval of DIF for the treatment of severe preeclampsia could have a significant impact on the lives of high-risk pregnant women and their babies, and the therapy would nicely complement AMAG’s existing portfolio of maternal health products. ...focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, ... Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.
AMRN (T/$7-10) Ireland drug manufacturer... company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.
***APDN (T/$6) Applied DNA Sciences Inc.
APRI (T/$4-5) commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company also engages in developing RayVa, which is in Phase 2 development for the treatment of Raynaud's Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. It operates in Europe, Canada, Latin America, and the Asia Pacific.
**ARNA (T/$19H) ...weight loss drug...pulmonary arterial hypertension...auto immune disease...ulcerative colitis
*****ARLZ (T/5-6) Aralez Pharmaceuticals June 7, 2017, Aralez announced the national commercial launch of Zontivity® in the U.S. The company had previously commenced a phased launch of Zontivity® in late April 2017 with 15 sales representatives targeting high volume physicians who treat post-myocardial infarction and peripheral artery disease (PAD) patients. .. Following a very rough first half of 2017 for Aralez, it appears as though the company has at least stabilized, and may be in the process of heading in the right direction. The early numbers for Zontivity® look promising, and the company’s focus on high-risk PAD patients may end up paying dividends. While YOSPRALA® is unlikely to ever live up to its original billing, its nice to see patients and prescribers responding favorably to the new pricing strategy. We will continue with updates on sales for Zontivity® and YOSPRALA® throughout the year, and are cautiously optimistic this may be the beginning of a turn around for the company. Our valuation remains $6.00, and now may be a good time for those with a high-risk tolerance to consider an investment in Aralez.
*****AUPH (T/$10-14) ...treatment lupus nephritis ....new duration-of-remission data from a mid-stage study that's good enough to suggest it could eventually change how doctors treat kidney failure in lupus patients. In the United States, there are over 500,000 people with systemic lupus erythematosus (SLE), and up to 60% of these patients will develop LN, or inflammation of the kidneys that can lead to end-stage kidney disease. Today, patients with LN are treated with steroids and CellCept, but for many patients this approach falls short. Steroids can result in unwanted side effects, and CellCept's efficacy can be hit-and-miss.Because current treatments are inadequate, there's an important need for new treatments, and based on Aurinia Pharmaceuticals' trial data, that need may be addressed by voclosporin. Earlier this year, the company reported that adding voclosporin to CellCept improved patient response rates and reduced patients' need for steroids. Specifically, the two-drug combination delivered a complete response rate of 49% at the 23.7 mg dose that was far better than the 24% complete remission rate observed in the trial's control group. https://www.fool.com/investing/2017/06/17/new-data-suggests-aurinia-pharmaceuticals-is-onto.aspx ... https://www.fool.com/investing/2017/08/17/3-reasons-to-buy-aurinia-pharmaceuticals-stock-rig.aspx?yptr=yahoo
*******AVXL (T/$10-16) Anavex Life Sciences ...Sept. 05, 2017 Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL) today announced that the United States Patent and Trademark Office has issued U.S. Patent Number 9,750,746 entitled “ANAVEX 2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection.“ This patent provides the Company with intellectual property protection covering composition of matter for ANAVEX™ 2-73 directed to a novel and synergistic neuroprotective compound combined with donepezil. The issued patent offers protection through 2033.“This newly issued patent expands the proprietary position of ANAVEX™ 2-73,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “This new patent is a continuation of Anavex’s vigorous pursuit of intellectual property protection for our neuroprotective therapeutics and we look forward to continued progress, including advancing ANAVEX™ 2-73 in clinical studies this year.“ ANAVEX™ 2-73 is an orally available, small-molecule activator of the sigma-1 receptor which, data suggest, is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.1 Donepezil is currently the leading compound for the treatment of Alzheimer’s disease in more than 50 countries and is postulated to exert a therapeutic effect by enhancing cholinergic function. ANAVEX™ 2-73 is to advance this year into a Phase 2/3 clinical trial for the treatment of Alzheimer’s disease, as well as other neurodegenerative and neurodevelopmental CNS indications, including the orphan designation Rett syndrome.
1 Advances in Experimental Medicine and Biology Volume 964 2017 Sigma Receptors: Their Role in Disease and as Therapeutic Targets
About Alzheimer’s disease
Alzheimer's disease is a progressive, irreversible neurological disease and the most common cause of dementia. In the U.S., there are over five million individuals living with Alzheimer's disease and an estimated 50 million people live with dementia worldwide. Today, there are no commercially available therapies to address the underlying cause of Alzheimer's. According to the World Alzheimer Report 2016, the global cost of dementia was $818 billion in 2015 and is expected to become a trillion-dollar disease by 2018.
The Company's SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer's disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. ...drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of Alzheimer's disease; and preclinical stage to treat Parkinson's disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. To our knowledge, this is the first use of this approach in the design of clinical trials for Alzheimer’s disease, Parkinson’s disease and Rett syndrome, and marks a shift towards advancing implementation of precision medicine for these and other neurodegenerative and neurodevelopmental diseases." BLRX (T/$3)... stem cell etal...
*****AXSM (T/$14-18) (fv $4.79)...fast track designation Tx for agitation in patiennts with alzheimer disease...
BCRX (T/$7-10) develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relation Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors
**BLFS hypothermic storage and cryopreservation cells and tissues, reduce post-preservation necrosis and apoptosis...Bothel,Wa.
BLPH (T/$5)... new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC. The company also presented preliminary data from a second, ongoing study evaluating INOpulse in COPD patients with Pulmonary Hypertension (PH-COPD). “Pulmonary Hypertension with IPF or COPD has no approved therapies and has been associated with increased hospitalizations and mortality. The therapies used in other pulmonary hypertension populations, which act systemically, have failed to show a benefit for these patients, creating a critical unmet need for effective and safe long-term treatment options,” said Prof. W. De Backer MD, Director in the Department of Pulmonary Medicine, University Hospital and University of Antwerp. “Pulsed iNO has a potentially unique and distinguishing advantage as the data from these trials shows that it can provide selective vasodilation to the well-functioning parts of the lung, allowing for improvement in hemodynamic measures as well as increased exercise capacity without worsening oxygenation.”
*****APHB (T/$5) AUG. 21, 2017 =AmpliPhi Biosciences Corporation (NYSE MKT: APHB)
, a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces publication of a case study highlighting the successful treatment of a critically ill patient with a multidrug-resistant (MDR) Acinetobacter baumannii
) infection. The manuscript, “Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii
infection,” was published in the peer-reviewed journal Antimicrobial Agents and Chemotherapy
and can be found here
. This case study was also featured in a July 2, 2017 Washington Post
article, which can be found here
. The case study details a patient suffering from an abdominal A. baumannii
infection whose condition deteriorated over a four-month period, despite multiple courses of antibiotics, and became comatose. AmpliPhi was involved in a joint effort, which included several academic institutions and a U.S. Navy laboratory, to produce a bacteriophage therapy targeted to the bacterial strain infecting the patient. The therapy was administered under a U.S. Food and Drug Administration (FDA) Emergency IND, and the patient emerged from his coma. The infection was cleared and the patient returned to health.
Robert T. “Chip” Schooley, M.D., Professor of Medicine at University of California, San Diego, who treated the patient and is the corresponding author of the paper, remarked, “Phage therapy is a very well-tolerated and potent therapeutic approach that can benefit patients with multidrug-resistant bacterial infections. It has the potential to help patients with multiple types of infections who have limited therapeutic options and, as a consequence, face severe disability or death." “At AmpliPhi, we are now developing our lead therapeutic candidates, AB-SA01 and AB-PA01 targeting multidrug-resistant S. aureus
and P. aeruginosa
infections, under expanded access guidelines by treating individual patients who have failed multiple courses of antibiotics and have few or no satisfactory treatment options,” said Paul C. Grint, M.D., CEO of AmpliPhi Biosciences. “We expect this strategy to validate the clinical utility of our therapies by early 2018 and position us to initiate further efficacy clinical trials later that year.” BPMX
() NO DEBT BVXV () ... focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. The company offers M-001, a synthetic peptide-based protein, which is in Phase 2 clinical development stage targeting seasonal and pandemic strains of the influenza virus. Phase-3 inTandem3 clinical trials The study demonstrated that sotagliflozin 400 mg was superior to the placebo in the patients with A1C <7.0% at Week 24. The study also did not record any episode of severe hypoglycemia or diabetic ketoacidosis (DKA) after randomization. Severe hypoglycemia is a diabetic emergency where blood glucose level becomes so low that patients need help from another person for treatment. Diabetic ketoacidosis is a serious diabetes complication where the body produces excess blood acids (ketones). “Strategy for approving a universal flu vaccine” in the journal Future Virology (Ben-Yedidia et al., 2017). The authors discuss the strategy to get M-001 through the regulatory process by using a stepwise approach that first utilizes an existing regulatory marker before using newly defined markers. Currently, the efficacy of all seasonal influenza vaccines is tested based on induction of hemagglutination inhibition (HAI) antibodies that target the outer variable regions of the viral hemagglutinin protein. Since M-001 is targeted against conserved regions of the influenza virus, it does not elicit HAI antibodies but instead induces a cellular response. Thus far, BiondVax has taken the conservative approach of using M-001 as a primer to be given ahead of the seasonal influenza vaccine. This has allowed the HAI antibody response to continue to be used to verify the efficacy of M-001. When given has a primer, M-001 enhances and broadens the HAI antibody response induced by the seasonal influenza vaccine. CANF
(T/$6) Can Fite Biofarma... Company develops new treatments for autoimmune diseases and cancer. The Company's drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. ****CAPR (T/$2) Capricor Therapeutics, ...granted FDA Rare Pediatric Disease Designation for CAP-1002, the company’s treatment for Duchenne muscular dystrophy (DMD) and cardiology indications. In reaction, CAPR stocks soared by 132%. CDTX (T/$10-14-20) ...class of antifungals for the treatment and prevention of serious, invasive fungal infections. The company also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid. In addition, it develops a proprietary immunotherapy technology platform Cloudbreak, which is designed to create compounds that direct immune system to attack and eliminate bacterial, fungal or viral pathogens. CATB (T/$4-9)...Cystic Fibrosis... also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. CBAY
(T/$12-15) liver disease...most significant was the lack of safety concerns associated with the drug ****CBIO (T/$11) focuses on developing medicines to address hematology indications, ... hemophilia ****CERS (T/$7-9) ommercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally CLBS (T/$7) ...provides development and manufacturing services to the cell therapy industry in the United States... also developing CLBS03, a T regulatory cell clinical Phase II therapy targeting adolescents with type 1 diabetes. *****CHRS (T/$40) Coherus BioSciences, Inc. shares dropped sharply to close the week down 28% to $14.85 following its announcement that the FDA issued a CRL (Complete Response Letter) for its Biologics License Application (BLA) for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate. No further trials were requested by the FDA and the company expects to respond to the agency in the coming months. The market for biosimilars
-- drugs designed to be interchangeable with branded biologically based medicines -- is expected to become one of the fastest-growing segments of the pharmaceutical industry over the next decade. After all, there is $100 billion worth of biologically based drugs on the market that have either lost exclusivity or will lose patent protection by 2020, according to a report by Markets and Markets.
Unfortunately, there aren't a lot of great ways for American investors to gain direct access to this emerging market. The late-stage biologics company Coherus Biosciences, however, is one glaring exception.
Coherus is presently working on resolving the outstanding issues regarding its regulatory filing for a biosimilar to Amgen
's megablockbuster bone marrow drug Neulasta. The good news is that U.S. Food and Drug Administration reportedly isn't going to require the company run any additional trials in order to refile its application. So, depending on the nature of all the outstanding issues, Coherus could have an FDA-approved biosimilar for a top-selling drug on the market within the next twelve months. Although it's hard to say how much of the Neulasta market Coherus can actually capture with its copycat medicine, the drugmaker's shares should get a nice boost even if it only goes on to grab a couple hundred million dollars in annual sales at peak. Coherus, after all, presently sports a market cap of a mere $794 million following its latest dip in the wake of that regulatory setback. In all, Coherus is well-positioned to take advantage of the rapidly evolving biosimilar market, making it an outstanding growth play for savvy investors
. Coherus is researching copycat versions of a handful of multi-billion dollar drugs, including Amgen's Neulasta and Enbrel as well as AbbVie's Humira. If Coherus succeeds at bringing one of these drugs to market and can steal even a small amount of market share then it could be a financial bonanza for the business. https://www.fool.com/investing/2017/06/16/3-stocks-that-could-double-your-money.aspx?yptr=yahoo http://stockcharts.com/c-sc/sc?s=CHRS&p=D&yr=1&mn=0&dy=0&i=p48111706416&r=1497823356920 *****CMRX (T/$8) (fv $7.65oral antivirals herpes virus and adeno virus. ****CNAT
(T/$9-18) ...Liver disease ****CORT
() Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor.
...(Motley Fool ... Roughly 90% of biotech stocks aren't profitable, but Corcept isn't part of that group. The company's only Food and Drug Administration-approved product is Korlym, a treatment for Cushing's syndrome.
Specialty drugs typically have very strong pricing power and minimal competition, suggesting that the company will be able to grow sales both organically in terms of volume, and via price increases, in the years to come. Because of that, it's forecast that sales will nearly triple between 2016 and 2020 to approximately $211 million.
If there is one concern with a company like Corcept, it's that the company is reliant on a single drug. But there are two key catalysts that could change that. To begin with, Corcept ended the first quarter with nearly $57.3 million in cash and cash equivalents ($47 million in net cash), and it's probably on track to generate in the neighborhood of $25 million in annual free cash flow over the next couple of years. This would give Corcept somewhere near $150 million in net cash, if not more, to work with by the end of the decade -- funds it could use to fuel internal research, or potentially even purchase new therapies to broaden its portfolio. Investors also shouldn't overlook the outside chance that Korlym's profitability and Corcept's net cash position might act as a dangling carrot, luring in larger acquirer.
The other catalyst is Corcept's pipeline, which offers a number of next-generation products that, like Korlym, block glucocorticoid receptors, but that have potentially fewer side effects. Some of these studies are focused on breast cancer in combination with a chemotherapeutic agent, Alzheimer's disease, and muscular dystrophy. Many are still in the very early stages, but they offer the promise of a more diverse portfolio to come. **CPRX
(T/$5) Catalyst Pharmaceuticals,Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy. *****CTRV
(T/$4) Hepatitis B CYDY
(T/$2) CytoDyn Inc ...focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man. CYTK
(T/$24) Cytokinetics, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. ****CYTR
(T/$10) scleroderma etal... DRRX (T/$3) Durect Corp... DVAX DVAX(T/$26)Dynavax hepatitis B vaccine, skin cancer... ®***Nov 10th will find out by August 10 if the FDA approves the drug for use on hepatitis B patients.
EBS...(T/$40) Emergent BioSolutions,Biodefense division... BioThrax to treat anthrax disease; Anthrasil treatment of inhalational anthrax; BAT treat botulinum disease; VIGIV address adverse events from smallpox vaccination; RSDL removal or neutralization of chemical agents, T-2 toxins, and various pesticide-related chemicals from the skin. NuThrax, next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 compound in the EV-035 series of broad spectrum antibiotics for Burkholderia pseudomallei; VAX161C, a recombinant pandemic influenza vaccine; PreviThrax, a recombinant protective antigen anthrax vaccine, as well as other products addressing public health threats and emerging infectious diseases. Its Biosciences division markets IXINITY prevent bleeding episodes in people with hemophilia B; WinRho SDF treat autoimmune platelet disorders and hemolytic of the newborn; HepaGam B post-exposure prophylactic treatment of hepatitis-B; VARIZIG post-exposure prophylactic treatment of varicella zoster virus. This division's investigational stage product candidates include otlertuzumab, protein therapeutic for Chronic Lymphocytic Leukemia; MOR209/ES414 metastatic castration resistant prostate cancer under collaboration with MorphoSys AG; ES210, a protein therapeutic for inflammation-related indications; 5E3, a monoclonal antibody therapeutic for Alzheimer's disease; and other protein therapeutic product candidates primarily for the treatment of immuno-oncology. The company also provides contract manufacturing services to third-party customers. ****EDGE (T/$21) Developing a sustained-release therapy for limiting brain injury after aneurysms. ***ENDV (T/1.50)... Bioelectronic device, treat acute liver failure (ALF) and other inflammatory conditions in vital organs ... stem cells... **** EYEG
(T/$10/) Diseases of the eye... ocuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. FBIO
(T/$11) Fortress Biotech The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109. FOLD AMICUS Therapeutics...biotech rare diseases... GEMP
(T/$18) clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. GLMD
(T/$18) liver disease GNCA
(T/$12-40) ....THIS IS A $6 STOCK today...Genocea Biosciences, lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus. https://finance.yahoo.com/news/cowen-sings-praises-genocea-biosciences-211052793.html The reason? Genocea announced data from GEN-003 Phase 2b trial in HSV2 demonstrating significant reductions in several measures of genital lesions through 12 months. Nadeau commented, "We are optimistic that GEN-003 will succeed in Phase III, and think that it addresses a significant commercial opportunity. The CDC estimates that 16% of the U.S. population aged >14 has been infected with HSV-2 and that 20-25% of infected people are aware of their status. This implies that GEN-003 could address a market oppy of 8MM - 11MM people in the U.S. alone. Assuming a price of $300 per course, GEN-003's total addressable market would be $2B+." (07/24) All the 5 analysts polled in the past 12 months rate Genocea stock a Buy. With a return potential of 323%, the stock's consensus target price stands at $24.67. ***
June 26th FDA...HALO
(T/$14-20) ... focused on creating products that help other drugs work better ...The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. Recent share dilution...10million shars sold $12.50 below market price $14.16... ** HEB biotech for the treatment of viral and immune based chronic disorders...chronic fatigue syndrome=myalic encephalomyelitis
(T/$3.25) Kadmon Holdings markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; co-promotes a product for chronic weight management; distributes products for chorea, cytomegalovirus retinitis, and for the prevention of CMV disease. It is also developing product candidates in autoimmune and fibrotic diseases, oncology, and genetic diseases.
KMDA (T/$7) AUG. 28, 2017 ...Kamada FDA has approved Kedrab [rabies immune globulin (Human)] for post-exposure prophylaxis against rabies infection. The company will launch Kedrab in the United States in early 2018. ***HZNP (T/$13H) ...arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. MESO
() specialized cells, known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, orthopedic disorders, and oncologic/hematologic conditions. MCRB
(T/11) Burn treatment... MDXG
(T/$18) The Company's gross margin for the quarter ended June 30, 2017, was 89%, as compared to the 87% gross margin in the second quarter of 2016. MiMedx is the leading supplier of placental tissue, having supplied over 900,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare MiMedx Group, Inc. develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin, and bone. The company collects the donated human placental tissue and converts into a sterile product through its proprietary PURION process. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry ***MHTX () nanomedicine... *** MNKD commercial-stage diabetes drug and device maker.... **MRNS 1.13 low (T/$3) biopharm epilepsy and neuropsychiatric disorders... MNTM Anti-Aging Drug .... MTNB (T/$6) ...focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease NAVB (0.60) Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI). NBRV (T/16) ...Developing a novel antibiotic for bacterial pneumonia. NBY (T/5-6) ...arkets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. *****NEOS (T/$8H-15) treatment of attention deficit / hyperactivity disorder (ADHD)Given... FDA approval Juner 19th “With this approval, Neos will be the only company to have both a branded methylphenidate and a branded amphetamine product available in an extended-release orally disintegrating tablet dosage form. We look forward to having Cotempla XR-ODT join our Adzenys XR-ODT®(amphetamine) extended-release orally disintegrating tablets on the market this fall.” Neos Therapeutics is a small-cap pharmaceutical company developing modified-release drugs for the treatment of ADHD and other neurodevelopmental disorders. Currently, the company's only approved branded product is Adzenys XR-ODT, an orally dissolvable tablet (ODT) form of extended-release amphetamine indicated for treatment of attention deficit / hyperactivity disorder (ADHD). Since its launch in May of 2016, sales of Adzenys have been growing well, with a total of 32,296 prescriptions filled between the months of January through March of this year. Monthly prescriptions increased 20% month-over-month during this timeframe, with total Adzenys revenue coming in at $3.1 million. As the company estimates that 54% of kids have difficulty swallowing tablets or capsules, and the total ADHD medication market to be worth $10.4 billion, these sales could have much more room to grow. NEOT Neothetics...LIPO-202 phase 2 TRIALS. ..specialty pharmaceutical company, develops therapeutics for the aesthetic market. Its lead product candidate is LIPO-202, an injectable formulation of salmeterol xinafoate for the reduction of localized fat deposits under the chin, treatment of attention deficit / hyperactivity disorder (ADHD). submental fat, as well as for reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. *NNVC nano-biopharmaceutical viral infections, shingles cream will be its first drug to start human testing... NTEC
(T/$10) ...Parkinson treatment... NVAX (T/$1.50) (insider buying 05/11) recombinant nanoparticles vaccines... NSTG NanoString Tech (biotech)NVCR (T/$15) Mesothelioma
OCRX...Ocera Therapeutics (T/$3-4) (fv $1.69) treatment of hyperammonemia and resultant hepatic encephalopathy *****OCLR (T/$35) OCULAR THERAPEUTIC JULY 19th FDA should approve Dextenza that treats eye pain after surgery... OMER... (T/$15H-22H) ...pupil-dilating drug called Omidria, which helps eye surgeons perform cataract removal and lens replacement procedures. While the initial ramp-up was slow, Omidria's sales growth exploded by 212% last year to $41.4 million -- and that could be just the beginning. Since millions of eye surgeries are performed every year, it's possible that Omeros could have a blockbuster on its hands. Omeros is a compound drug called OMS721. This product candidate is being researched as a treatment option for a number of disorders that includes atypical hemolytic-uremic syndrome (aHUS). There is currently only one treatment option for this ultra-rare condition: Alexion Pharmaceuticals' Soliris. Alexion rang up more than $2.8 billion in total Soliris sales last year in part because of its aHUS monopoly. That hints that OMS721 could potentially ring up nine figures in sales on its aHUS opportunity alone. *****ONCS (T/$3-5) ...gene therapies...electroporation delivery device, melanoma... ONTX 1.78 low(T$5.00) (fv $2.39)Onconova targets RAS cellular pathways which have been linked to cancer cells while causing minimal damage to healthy cells.
***OPK (T/$6-11-20) CEO Frost is buying up all the shares... clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products
***ONVO ONVO human tissues that could be employed in drug discovery and development, tissue patches for repair or replacement damaged tissues/organs... tissue assay toxicities would help companies not have to run Phase 1 trials...
OPGN OpGen... VAL-083, an oncology drug for the treatment of refractory glioblastoma multiforme. The company is set to meet with the FDA before the close of the quarter to discuss a Phase 3 study design and has already picked up orphan designation for the drug. On May 5, DelMar reported the closing of a private placement that saw the company pick up gross proceeds of $5.6 million. No company, biotech or otherwise, raises equity-based capital specifically to drive sales efforts if it doesn’t believe there is a thriving market for the product. That OpGen has picked now to raise in order to spend on marketing, and that markets have been responsive to its issue, is indicative of recovery. ****OPK 5.99 low...hemophilia, human growth hormone ****ORMP(T/$25) Oramed Pharmaceuticals ... field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. OvaScience (OVAS), NovaBay Pharmaceuticals (NBY), Novogen Limited (NVGN), Prana Biotechnology Limited (PRAN), Caladrius Biosciences (CLBS), ImmunoCellular Therapeutics Ltd (IMUC), Pharmacyclics (PCYC) . ****PGNX (T/$14) neuroendocrine tumor affects the hormone-producing cells of the body’s neuroendocrine system that comprises of cells which are a combination of hormone-producing endocrine cells and nerve cells. These cells control the flow of air, blood and food through the different body parts. There are no approved therapies available in the U.S. market for the two diseases. PIRS (T/$9-10) ...proprietary technology, called Anticalins. They are a mimetic antibody that can be used in many of the same ways antibodies can be used but that are far smaller than antibodies and – as a result – can be applied to a far wider range of indications. https://www.insiderfinancial.com/pieris-pharmaceuticals-inc-nasdaqpirs-has-a-near-term-catalyst-that-could-see-it-run-higher/123540/ The company’s strategy is simple – create a treatment based on this technology then find a big name to pay for the rights to it. Execution of this strategy has, so far, been flawless. Pieris has deals in place with Roche Holding Ltd. (VTX:ROG), Sanofi SA (ADR) (NYSE:SNY), Servier and, as per our last coverage, AstraZeneca plc (ADR) *PRAN biotech development of therapeutic drugs in Australia... *****PSDV (T/$9) pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases. AZN ***May 3, 2017 $57 million deal). The combination of these partnerships has the potential to bring more than $4 billion milestone dollars to Pieris and right now the company trades for a market capitalization of less than $200 million. Well, we’re holding out for some fresh partnership announcements, but that’s not all we’ve got our eye on. There’s a near-term data release that could drive this one into the $7-10 range on its release (conservatively) if it hits press as positive. The drug is called PRS-080 and it’s targeting anemia. Back in February, Pieris struck a deal with Japanese drugmaker ASKA Pharmaceutical Co that saw the latter pick up the rights to the drug in Japan and other Asian regions. Pieris retained the rights in the US and Europe, and the drug advanced into a phase IIa multiple dose study almost immediately after the deal hit press. Data from this trial is expected to be released during the third quarter of this year (latest communication says second half 2017, but trial length/expected completion can be used to narrow this a little). PSTI
(T/$2) ...manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. The company develops placenta expanded (PLX) cell therapy products, such as PLX-PAD cells, which has been completed Phase-II clinical trial for the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. It also develops PLX-R18 cells for hematopoietic cell transplantation in animals, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS ******PULM (this may be a sleeper)
...Pulmatrix has developed a technology that allows for the encapsulation of an active compound and the delivery of this encapsulated active compound through an inhaler. The technology is called iSperse, and it is designed to overcome some of the drawbacks associated with inhaled active compounds in standard of care treatments. Specifically, and primarily, these drawbacks are rooted in the active compound clumping up at the back of the throat post-inhalation and causing two distinct problems: one, not enough active drug reaching the lungs (and in turn, a lack of efficacy) and two, toxicity-associated side effects caused by the collection of the active compound at the back of the throat. The iSperse technology, for want of a better phrase, lubricates the active compound so it won’t stick together and doesn’t clump, and by proxy, doesn’t get caught in the throat. This allows for a more compact dose in various indications, as less of the active compound needs to be inhaled to have the same amount of it (when compared to standard of care) reaching the lungs. The primary application of this technology right now is in COPD (Cronic Obstructive Pulmonary Disease). http://ir.pulmatrix.com/Zacks-Initiates-on-Pulmatrix-NASDAQ-PULM QBIO story stock glaucoma drug... RIGL
(T/$5) development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. ROKA (T/$10)(NEW LOW )Roka Bioscience molecular assay technologies for the detection of foodborne pathogens ****SBOT (T/$4)... Biotech...keyhole limpet hemocyanin (KLH) protein... POTENTIAL GAME CHANGING TREATMENTS OF SERIOUS DISEASES...When you're developing a vaccine for any indication, you can have a dendritic cell vaccine, you can have a DNA-based vaccine, you can have a KLH-based vaccine or a peptide vaccine, and each one has its own advantages, disadvantages and attributes that you may or may not want as part of the immune response you are targeting. KLH seems to be geared toward generating antibody responses versus T-cell responses. *** SGYP...(T/$9-11-13-15)Synergy Pharmaceuticals ...therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome SNGX (T/$4) ... objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax®, in combination with the Company's ricin toxin vaccine, RiVax®, as a medical countermeasure to prevent the effects of ricin exposure. SRNE...Sorrento Therapeutics STML
(T/$11) TTNP Pharma... treatments for chronic diseases, such as Parkinson's disease. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment. TXMD (T/$10-20) ...hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. ***TTPH
(T/$14) Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a second-generation Gram-negative program, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. In addition, the company is involved in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. VCEL
(T/$6) ... markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. VRX
(T/$13-15) treatment Alzheimers
and type 2 diabetes ... vTv Therapeutics Inc. (VTVT
) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using azeliragon, the Company’s oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer’s disease. The patent number is 9,717,710 (‘710 Patent).The ‘710 Patent, expiring in October 2034, includes claims covering methods of treating patients with mild Alzheimer’s disease by administering about 5 mg per day of azeliragon. vTv expects that the ‘710 Patent will be Orange Book listable. The ‘710 Patent adds to the portfolio of US patents covering azeliragon, including a composition of matter patent that is expected to expire in 2029. vTv continues to prosecute additional patent applications to further enhance its existing patent portfolio covering azeliragon.
“vTv is currently the only company developing a treatment for Alzheimer’s disease by targeting the RAGE receptor, which has demonstrated potential in addressing three key pathologies in Alzheimer's disease: amyloid-β, tau and chronic inflammation,” said Steve Holcombe, president and CEO of vTv Therapeutics. “This new patent is an important milestone as vTv prepares for the results of our upcoming Phase 3 data readout.”
Azeliragon is currently being studied in a randomized, double-blind, placebo-controlled Phase 3 trial investigating the efficacy of azeliragon as a potential treatment to slow the decline in cognition and functional activities for patients with mild Alzheimer’s disease. Data from Part A of the trial is expected to read out in late March 2018, data from Part B data is expected to read out in late December 2018.
Gene Therapy ... http://www.bizjournals.com/boston/news/2017/05/30/study-raises-concerns-over-gene-editing-hitting.html?ana=yahoo&yptr=yahoo CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. According to the Broad Institute, these are the hallmark of a bacterial defense system which forms the basis for the popular CRISPR-Cas9 genome editing technology. In the field of genome engineering, CRISPR is often used loosely to refer to the entire CRISPR-Cas9 system, which can be programmed to target specific stretches of genetic code and to edit DNA at precise locations. The gene editing technology CRISPR/CAS9 is being used to develop a host of new treatments, mostly for genetic diseases. But a team of researchers from the University of Rochester's Center for RNA Biology are investigating whether gene editing can be used for another purpose: to slow the growth of cancer cells. ****BTX
(T/$6) ... addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. CRSP (T/$23.50) CRISPER Therapeutics AG (Buy rating and price target $23.50 by Chardan Capital) ... focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. Both sides claim victory — angling for millions in potential royalties and licenses — in gene-editing patent dispute 02/16/2017 *EDIT (T/$33-65???) (on hold until MID 2018) Editas Medicine... Buy rating and $65 price target by Chardan. Biotechnology...the ability to play God...gene therapy.... Editas Medicine is a company that should be on a lot of radars, as they’re working on a revolutionary method of genome editing which could conceivably provide cures for the approximately 6,000 diseases which are caused by genetic mutations in our DNA. Of those, only about 5% currently have approved therapeutic treatments (and those don’t address the root cause, but seek to combat the symptoms). Editas’ genome editing platform CRISPR could instead be used to correct the genetic problem at its source: right in our DNA. A protein-RNA complex can be tailored to either repair or replace damaged genetic sequences, and is then guided to the target spot in the genetic link by a guide RNA. The result is a corrected sequence that could completely cure the issues that were being caused by the defect.There are a couple issues surrounding the company however. Firstly, it could be years before any human trials of the platform are launched. Secondly, Editas Medicine is currently caught in the middle of a heated patent dispute over the CRISPR platform itself, which teams of scientists from Berkeley and the Broad Institute each claim to have the patent rights to. Interestingly, members of both of those teams helped found Editas and still serve as founding scientific advisors for the company.Setting aside the patent dispute, there’s some exciting work being done at Editas that could revolutionize medicine, making this one of the most interesting companies in the world. *NTLA (T/$19) Intellia Therapeutics ...lead target is liver disease ...Intellia Therapeutics Inc is a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product ...headquartered in Cambridge, Massachusetts. ***CLLS (T/$49) (fv$19-50) Cellectis...focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that U.S. patent 8,921,332, which claims the use of chimeric restriction endonucleases for directing chromosomal gene editing in cells by homologous recombination (HR), initially issued on Dec. 30, 2014, has been upheld by the United States Patent and Trademark Office (USPTO) after a reexamination initiated in October 2015. U.S. patent 8,921,332 claims a general method for modifying chromosomal DNA sequences at a genomic site of interest within a cell by using a chimeric restriction endonuclease such as zing finger nucleases, TAL-effector nucleases, Mega-TALs and CRISPR/Cas9. This technique, commonly referred to as gene targeting or targeted insertion, is now frequently used to modify the genome within plants, animals and cell lines. OPGN
() OpGen, Inc. 06/05/2017 announced the results from additional studies supporting the capabilities of its Acuitas Rapid Test and Acuitas Whole Genome Sequence Analysis to accurately predict antibiotic resistance and for infection control *****QURE (T/$-13) uniQure... The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. *****ABEO (T/$14-17-22) Abeona Therapeutics ...developing novel gene therapies for life-threatening rare genetic diseases. The Company's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process. Some companies that are related to Abeona Therapeutics include Advaxis (ADXS), NewLink Genetics Corp (NLNK), Compugen (CGEN), Oramed Pharmaceuticals ABUS
(T/$6-10 ) developing and commercializing a cure for patients suffering from chronic hepatitis B infection , a disease of the liver caused by the hepatitis B virus (HBV). It currently has negative earnings. It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology.
HSGX (T/$4) Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
APTO (/$4) develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, a small molecule that induces the transcription of the Kruppel-like factor 4 Gene in in vitro studies and in in vivo pharmacodynamic studies of human xenograft tumors in mice. The company's APTO-253 clinical program has completed Phase-I clinical trials for the treatment of various solid tumors; and Phase-Ib clinical trials for relapsed/refractory hematologic malignancies. It also develops APTO-500 program that focuses on discovering and developing small molecule inhibitors of maternal embryonic leucine zipper kinase; and is in a pre-clinical stage for oncology. It has a license agreement with Genentech Inc. to develop and sub-license a specified polypeptide; and collaboration agreement with Eli Lilly and Company to investigate a proprietary series of the company's compounds for veterinary medicine. *****AST (T/$6-12)Stem Cell regenerative medicine neuro...https://finance.yahoo.com/news/asterias-biotherapeutics-completes-enrollment-dosing-110000202.html The Company has two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.
ATHX (T/$9) focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. AXGN
(T/$22) AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
BLRX... **BCLI (T/$8) Brainstorm Cell Therapeutics ...adult stem cell therapies for neurodegenerative disorders ALS...engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally.
*****BPTH (T/$5) NO DEBT Bio-Path Holdings, Inc. (Bio-Path) is a clinical stage biotechnology company that focuses on developing nucleic acid cancer therapeutics using its proprietary nanoparticle RNAi antisense technology called DNAbilize™. This technology safely distributes nucleic acid based drugs systemically throughout the body via intravenous infusion. Bio-Path's lead product candidate, prexigebersen (BP1001) is in Phase 2 clinical studies for the treatment of acute and chronic myeloid leukemia (AML and CML), and preclinical studies for solid tumors. The Company's second DNAbilize™ drug candidate, Liposomal Bcl2 (BP1002), for the treatment of lymphoma, leukemia, colon, prostate and breast cancers, has completed preclinical studies for non-Hodgkin's lymphoma. Bio-Path is planning a broad Phase 1 clinical trial in lymphoma in 2017. Bio-Path is headquartered in Bellaire, Texas, and currently employs 12 full-time.
Despite ongoing advancements in the development of nucleic acid drugs, pharmaceutical developers are still facing the challenge of delivering therapeutics to targeted cells without causing severe side effects in the patient. In clinical studies, Bio-Path's therapeutic platform has delivered a strong, effective therapeutic payload, with no evidence of toxicity. This novel target-based platform has the potential to transform the therapeutic landscape of cancer treatment and also address other diseases that have well-defined targets.
- Bio-Path's pipeline continues to expand with new cancer indications. Importantly, once its DNAbilize™ platform is proven successful for cancer, the core technology can easily be expanded to address new therapeutic areas, including autoimmune diseases.
In contrast to other lipid delivery technologies that have dose-limiting toxicities, DNAbilize™, Bio-Path's next generation oligonucleotide-based technology, enables the delivery of high doses of therapeutics to target cells, while demonstrating no evidence of toxicity. This lack of toxicity enables the development of therapies to address patients, particularly within the growing elderly population, who are unable to withstand aggressive therapeutic regimens, and therefore, have limited available treatment options.
Bio-Path has completed Phase 1 clinical trials for its lead candidate prexigebersen for AML, CML and other blood cancers, and is in the midst of Phase 2 clinical trial for AML and a Phase 1b/2 clinical trial for CML. Importantly, the Company expects to complete an interim analysis in 2H 2017 of the first 19 patients enrolled in the Phase 2 efficacy trial for AML, with the possibility of switching to a registration trial for accelerated approval.
The clinical targets for BP1002 are lymphoma, and potentially breast cancer, colon cancer, and prostate cancer. This novel, non-toxic, specific Bcl2 inhibitor could be a significant advance in cancer therapeutics, with the potential to treat 40% to 60% of solid tumors, according to Bio-Path estimates.
Bio-Path is collaborating with respected academic and clinical institutions, including M.D. Anderson, Thomas Jefferson University and UT Southwestern, to expand indications inside and outside of cancer, which we view as a validation of Bio-Path's DNAbilize™ technology. Going forward, we believe the versatility of the DNAbilize™ platform could represent significant drug development and licensing opportunities for Bio-Path.
Recent results include a net loss of $397K for the quarter ended 3/31/17 vs. a net loss of $1.87M for the comparable quarter of prior year. While operating expenses were similar Y-O-Y, the Company recognized a $1.6M gain for the change in fair value of warrants for the most recent quarter. Management states that cash on hand of approximately $7M is sufficient to fund operations for the next 12 months.
With promising clinical data and several programs in the pipeline addressing sizable markets with unmet needs, our valuation analysis for the BP1001 for AML and CML programs alone results in an estimated range of $3.60-$4.45/share, with a mid-point of approximately $3.99. Stonegate Capital Partners BSTG () NO DEBT Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities.
BLRX (T/$3 ) BioLineRx Ltd.
Aug 21, 2017 /PRNewswire/ -- (BLRX
), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells
for autologous transplantation in patients with multiple myeloma. The trial, named GENESIS, is expected to commence by the end of 2017, following receipt of regulatory approvals. The Phase 3 GENESIS trial is aimed at evaluating the safety, tolerability and efficacy of the combination treatment of BL-8040 and granulocyte colony-stimulating factor (G-CSF), as compared to the control arm of placebo and G-CSF. The trial will be conducted in two parts: The first part, designed to validate the optimal dosing of BL-8040, is a lead-in, open-label, multi-center study that will include 10-30 patients, in order to assess the efficacy and safety of treatment with BL-8040 and G-CSF. This part will be followed by a randomized, placebo-controlled, multi-center study in approximately 180 patients. The primary endpoint will be the proportion of subjects mobilizing ≥6.0 x 106
CD34+ cells/kg with up to 2 apheresis sessions in preparation for autologous transplantation after a single administration of BL-8040 and G-CSF, as compared to placebo and G-CS
DMTX (T/$3.5) Developing novel, liver-directed gene therapies for rare genetic disorders.
FATE (T/$7) develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorderS. GNMX (T/$1.50-9) he company develops transduced autologous restorative gene therapy (TARGT), a platform to provide protein and peptide therapies to treat a range of chronic diseases. Its lead product candidate is MDGN-201, which is an endogenous erythropoietin secretion TARGT that is in the Phase I/II clinical trials for the treatment of end stage renal diseases and other indications, including ß-thalassemia. HALO (T/$7H) Halozyme Therapeutics, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer.
CUR (T/$3) 09/07/2017 ...Neuralstem...
awarded two additional patents by the United States Patent and Trademark Office (USPTO). These patents broadly protect methods for using neural stem cells to treat neurodegenerative disorders, a key component of the Company’s platform. The first new patent, U.S. Patent No. 9,744,194, covers methods of treating neurodegenerative disorders through transplantation of neural stem cells. The second new patent, U.S. Patent No. 9,750,769, covers neural stem cells engineered to express IGF-1, a neurotrophic molecule with broad therapeutic potential in the treatment of neurodegenerative disorders.
...development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from ...It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke.
MCAO ...stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. HSGX (T/$4) Histogenics Corporation, a regenerative medicine compa ny, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. HTGM (T/$6) instruments molecular profiling applications ...mRNA biomarkers...The HTG EdgeSeq ALKPlus Assay EU is an in vitro diagnostic intended to measure and analyze mRNA ALK gene rearrangements in formalin-fixed, paraffin-embedded lung tumor specimens from patients previously diagnosed with non-small cell lung cancer (NSCLC). This assay may be used to aid the identification of patients eligible for ALK-targeted therapeutics, such as crizotinib, and is automated on the HTG EdgeSeq system using a next-generation sequencer for detection. *****INO (T/$12-13)...Inovio Pharmaceuticals is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program and Laval University. Inovio Pharmaceuticals (INO
+0.4%) and Roche's (OTCQX:RHHBY) Genentech will collaborate on a clinical trial assessing the combination of INO-5401, a T cell-activating immunotherapy, and Tecentriq (atezolizumab) in patients with advanced urothelial carcinoma (bladder cancer). INO ...develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program. HYGS
(T/$5-9) Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
PSTI (T/$2) operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trials, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. The company develops placenta expanded (PLX) cell therapy products, such as PLX-PAD cells, which has been completed Phase-II clinical trial for the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. It also develops PLX-R18 cells for hematopoietic cell transplantation in animals, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS ONCS
(T/5-6) OncoSec Medical ...gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
KPTI ... RGLS
(T/2.50-$6) focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. **ROSG (T/$3.50H)(1:12 REVERSE SPLIT 03/17) Rossetta Genomics... MicroRNAs are a group of genes that are produced using instructions encoded in DNA. SNY ...the "immortality gene" treats cholestrol in adults hypercholestrolemia. ****SGMO
(T/$4-8-17) Sangamo Therapeutics
... in May the company announced a new collaboration with Pfizer in hemophilia A. The pair will work together to develop a gene therapy called SB-525, which has received orphan drug designations from the U.S. Food and Drug Administration and the European Medicines Agency. The company's proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies.
SB-525 is Sangamo’s clinical stage cDNA gene therapy candidate for hemophilia A. = fast-track designation from the FDA will facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill an unmet medical need. SB-525 already enjoys orphan drug status in the U.S. The FDA has cleared an Investigational New Drug application for this program, and a phase I/II clinical trial evaluating SB-525 in adults with hemophilia A is expected to open and begin screening subjects for enrolment by the end of second-quarter 2017. Data from this study are expected in late 2017 or early 2018.
SLNO (GOOGLE) issuance of a new patent (9,757,384) from the U.S. Patent and Trademark Office related to the use of pharmaceutical formulations of diazoxide and its salts, such as diazoxide choline, to reduce one or more aggressive behaviors in a subject with Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS). PWS is a rare and complex genetic neurobehavioral/metabolic disorder affecting appetite, growth, metabolism, cognitive function, and behavior. SMS is a rare disorder with a distinct genetic basis, but a natural history similar to that of PWS. “This patent will further strengthen the intellectual property portfolio for DCCR, our lead product candidate, for the treatment of PWS,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “Importantly, this most recent patent will provide protection of associated claims into 2035. We expect to leverage additional intellectual property opportunities for DCCR over the coming months.”
Soleno expects to initiate a Phase III clinical trial of Diazoxide Choline Controlled Release Tablet (DCCR) in PWS by the end of 2017. The Company is currently finalizing the design of a randomized, double-blind placebo-controlled study that will treat approximately 100 patients. This study is anticipated to take approximately 9-12 months to complete. DCCR has Orphan Designation for the treatment of PWS in the U.S.
PWS is a rare and complex genetic neurobehavioral/metabolic disorder affecting appetite, growth, metabolism, cognitive function and behavior. The committee on genetics of the American Academy of Pediatrics states PWS affects both genders equally and occurs in people from all geographic regions: its estimated incidence is one in 15,000 to 25,000 births. This disorder is typically characterized by hyperphagia, a chronic feeling of insatiable hunger, behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia, in the absence of effective limitations to access to food, can lead to morbid obesity. In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parent and caregivers) rated hyperphagia, which is the unrelenting hunger that severely diminishes the quality of life for patients and their families, as the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder.
About Diazoxide Choline Controlled-Release Tablet
Diazoxide choline controlled-release tablet is a novel, proprietary controlled-release, crystalline salt formulation of diazoxide, which is administered once-daily. The parent molecule, diazoxide, as an oral suspension, has been used for decades in thousands of patients in a few rare diseases in neonates, children and/or adults, but not in PWS. Essentialis conceived of and is pursuing an extensive patent portfolio relating to various aspects of the therapeutic use of diazoxide and DCCR in patients with PWS. The DCCR development program is supported by positive data from two completed Phase II clinical studies and five completed Phase I clinical studies in various metabolic indications, as well as a pilot study in PWS patients. In the PWS pilot study, DCCR showed promise in addressing the hallmark symptoms of PWS, most notably hyperphagia
ONCE... BLUE... SMMT
... SRPT... Nanopore Technologies (private company) OPGN
() in vitro diagnostic tests designed to identify antimicrobial resistant pathogens, as well as XpressFISH diagnostic test products for the identification of various infectious pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. MDXG
(T/$20)... MiMedx Group, Inc. develops, patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin, and bone. The company collects the donated human placental tissue and converts into a sterile product through its proprietary PURION process. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. PACB genetic sequencing machine *****SRNE
() Sorrento Therapeutics...primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy. VCEL (T/$6)
VTGN XON Intrexon Corp
is a leader in the bio-tech field. The company’s biologically-based products and processes are some of the most interesting and important revelations in the medical industry. Designing, building, and regulating gene programs, the company’s technological advancements are ahead of most.
One of Intrexon’s most important technologies is its patented UltraVector. The platform is a software-based operating system that accurately maps and assembles genetic programs. The platform allows for deeper understanding of how everything works and allows for experiments not possible otherwise.
As tech continues to fuel medical breakthroughs, Intrexon Corp is definitely worth keeping an eye on. Genetic-Agriculture *****AMRS
The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. The company serves health, food, energy, environment, and consumer sectors.
(T/$15) Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. CLXT
(T/$17) ...develops healthier specialty food ingredients and agricultural food crops using gene editing technology for plants. It engages in the development of high oleic soybeans, powdery mildew resistant wheat, cold storable potatoes, high fiber wheat, reduced browning potatoes, and herbicide tolerant wheat. YTEN () Yield10 Bioscience, Inc. is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems. Yield10 is leveraging its technology platforms and unique knowledge base to design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and corn.
Researchers used the CRISPR genome editing tool to inactivate an enzyme expected to increase seed oil content in Camelina, a trait Yield10 has designated as C3008. There are three copies of this gene in the Camelina genome and complete editing of all copies was achieved. This trait may have further applications when used in combination with other traits that the Company is developing that are expected to increase seed oil content, including C3007. “We believe that genome editing technology represents a fundamentally new way to rapidly deploy desirable, novel traits into commercial agricultural crops by specifically making small changes or removing small pieces of DNA to reduce the activity of target genes without leaving behind any foreign DNA in the plant,” CANCER *****ADXS (T/19-24) Advaxis ...Its LM therapies alter live strains of Listeria monocytogenes bacteria to generate cancer-fighting T cells targeting cancer antigens. Clinical trials have shown these immunotherapies to be well tolerated with anti-tumor activity, which could translate to a successful product or partnership in the future if successful in later trials. The downside is that the firm continues to burn cash as it develops its clinical pipeline... Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma. AEZS (T/2H -4 FOR 2018) AEterna FDA has accepted the drug maker's New Drug Application (NDA) for Macrilen (macimorelin), a novel orally-active ghrelin agonist intended to help in monitoring treatment for adult growth hormone deficiency (AGHD) ***AGRX (T/$10) SHARE DILUTION Aug. 3rd 5.33 million shares at $3.75 ...Women's contrception...weekly patch December 26, 2017 as the Prescription Drug User Fee Act (PDUFA) goal date. ****AFMD
(T/$7) ...its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. AGEN
(T/$7) Immuno-oncology ALRN
(T/$19-20) Lymphoma... ****APTO (?) Aptose Bioscience CG’806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3, demonstrated the superior potency of CG’806, relative to competitive agents, against hematologic malignancy cell lines driven by various WT or mutant forms of FLT3. In addition, once daily oral dosing of CG’806 in a murine model achieved sustained micromolar plasma concentration over a 24hr period, and was accompanied by complete elimination of AML FLT3-ITD tumors in the absence of toxicity. "Given the potency of CG’806 against all of the mutant forms of FLT3 AML and the ability to eradicate AML tumors in murine xenograft models, CG’806 has demonstrated the potential to be superior to other FLT3 inhibitors and is beginning to differentiate itself as a targeted treatment for AML," commented William G. Rice, Ph.D., Chairman and Chief Executive Officer of Aptose. “We believe CG’806 has the potential to become the best-in-class FLT3 inhibitor, and our internal efforts now are focused on delivering CG’806 to AML patients as soon as practicable.” ARRY (T/$10H-13) Array BioPharma Many drugs in the pipeline cancer...hepatitis C virus...myeloma and many gene cancer inhibitors... *****AST (T/$6-12)Stem Cell regenerative medicine neuro...https://finance.yahoo.com/news/asterias-biotherapeutics-completes-enrollment-dosing-110000202.html The Company has two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells. ATOS biopharmaceutical breast cancer Seattle... ATNM
() NO DEBT
*****news third quarter AVEO AVEO (T/$3H-$3.5H -4.50) kidney cancer ...European Medicines Agency (EMA) said experts at its Committee for Medicinal Products for Human Use (CHMP) had backed the oral, once-daily drug for marketing approval as a first-line treatment for advanced renal cell carcinoma, or kidney cancer. AVEO has made significant progress with its lead pipeline candidate, tivozanib. It is currently under review in the EU for the first-line treatment of advanced RCC. In Jun 2017, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of the candidate. A final response on the approval status of the candidate is expected in the third quarter of 2017. https://finance.yahoo.com/news/aveo-pharmaceuticals-aveo-q2-loss-142502771.html The company also announced achievement of enrollment target in a phase III study, TIVO-3, evaluating tivozanib, in June, ahead of its prior deadline of Aug 2017. Top-line data is expected in the first quarter of 2018. The study will compare tivozanib with Bayer’s BAYRY Nexavar in patients with refractory advanced renal cell carcinoma (RCC). The data from this study along with previously completed TIVO-1 study will support the regulatory application for approval of tivozanib in the U.S. as a first- and third-line treatment for RCC. ***BIOC cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample.... ****BPMX (T/$3) ...suggests that molecular iodine can specifically inhibit cellullar proliferation and drive cell death in certain breast cancer cell lines without apparent toxicity to normal breast cells. *****BPTH
(T/$2-5) Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. ***CALA (T/$9H)...small molecule drugs directed against tumor metabolism and tumor immunology targets... *****CANF
(T/$7) Can-Fite BioPharma
... Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is being evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug. Can-Fite has received Orphan Drug Designation for Namodenoson in Europe and the U.S., as well as Fast Track Status in the U.S. as a second line treatment for hepatocellular carcinoma.= excellent safety profile of the drug=
Data also showed that Namodenoson has a liver protective effect that is very unique compared to Nexavar® and other drugs under development for HCC which have shown to induce hepato-toxicity. According to Datamonitor, the market for hepatocellular carcinoma drugs is projected to reach $1.4 billion in 2019. Nexavar® annual sales, as reported by Bayer, were €870 million in 2016. The Company's lead drug candidate, Piclidenoson, is scheduled to enter a Phase III trial for rheumatoid arthritis in 2017 and a Phase III trial for psoriasis in early 2018. The rheumatoid arthritis Phase III protocol has recently been agreed with the European Medicines Agency. Can-Fite's liver cancer drug Namodenoson is in Phase II trials for patients with liver cancer and is slated to enter Phase II for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and is being prepared for an IND submission to the FDA and a Phase I trial. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date CGEN (T/$9-14) ... early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types ****CGIX (T/$6) Cancer Genetics...
Lung cancer is by far the leading cause of cancer death among both men and women; about 1 out of 4 cancer deaths are from lung cancer. It is the second most common cancer in both men and women (not counting skin cancer). About 14% of all new cancers are lung cancers, with NSCLC accounting for 85% of all lung cancers. It is estimated that in 2017, approximately 222,500 Americans will be diagnosed with lung cancer, and almost 156,000 will die from this disease.
Approved by the FDA on June 22 of 2017, the Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC. Following FDA approval, results from analysis of three of these genes can now be used to identify patients who may be eligible for treatment with one of the following: AstraZeneca's EGFR inhibitor Iressa (gefitinib), Pfizer's ALK and ROS1 inhibitor Xalkori (crizotinib), and the combination therapy of Novartis' MEK inhibitor Mekinist (trametinib) and RAF inhibitor Tafinlar (dabrafenib). With this test, physicians can now match patients to these therapies in days instead of several weeks, which it often takes when screening samples one biomarker at a time.
Recognized as Thermo Fisher's NGS CDx Center of Excellence, CGI is among the first 3 laboratories that will offer the Oncomine Dx Target Test as a service to oncologists. All tests will be run on Thermo Fisher's Ion PGM Dx System, which received FDA 510(k) clearance in parallel for use on formalin-fixed, paraffin-embedded (FFPE) tissue samples. The Oncomine Dx Target Test is a kit and requires as little as 10 nanograms of DNA from FFPE tissues samples - a critical advantage of the test, given the challenge of NSCLC patient samples often being of limited quantity. CHEK (T/$5-6) medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening for precancerous polyps and cancer.... CTMX (T/$25) Preclinical biotech developing tumor-activated cancer immunotherapies. CYTR () The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology DCTH () ...Delcath Systems, an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. I’d also like to highlight that the clinical potential of Melphalan/HDS in the treatment of ocular melanoma liver metastases was repeatedly supported by compelling clinical data presented and published throughout the past year. Most recently, a single-center retrospective review was published in the American Journal of Clinical Oncology in which the authors found that investigational PHP with Melphalan/HDS offered promising results with a doubling of overall survival (OS) and significantly longer progression-free survival (PFS) and hepatic PFS than other targeted therapies. In addition, an oral presentation at the Regional Cancer Therapies 12th International Symposium reported data from a retrospective, multicenter study demonstrating that 45.7% of patients with ocular melanoma that metastasized to the liver who underwent PHP using investigational Melphalan/HDS experienced a complete or a partial response. That same study further showed that among those who responded to treatment, OS was projected to be more than three years. The projected 657-day median OS and 1,207-day median OS in patients with a partial or a complete response is very impressive, and we believe speaks to the potential of our system to provide a meaningful and durable response in a disease that has an average survival of only six to eight months. *****DMPI DMPI (T/$13) DelMar Pharmaceuticals ... focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB). ****DMTX
($12) EXAS ...(T/27H) Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer ****EPZM (T/$20-25) ...Epizyme ... Recent activity appears promising and potentially supportive of accelerated approval, considering there is no established standard of care in the setting. There are 25,000 new cases of follicular lymphoma diagnosed in the U.S. annually, and up to 20% of those patients have the EZH2 mutation. Currently, patients are treated with chemotherapy plus Rituxan. However, most patients end up relapsing, and treatment options when the disease returns are limited. Therefore, the findings in these indications are particularly intriguing. https://www.fool.com/investing/general/2017/06/15/why-epizyme-incs-shares-are-skyrocketing-today.aspx?yptr=yahoo ****FBIO (T-9-11) Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its product includes CNDO-109, a lysate that activates donor natural killer cells for the treatment of cancer-related and other conditions. GALE
() NO DEBT ******GERN (T/$5) ... lead candidate, imetelstat, appears to have an important advantage over the leading treatment (Jakafi) for a rare form of blood cancer known as myelofibrosis, a disorder marked by overactive blood cell production in bone marrow. In a trial that enrolled 33 myelofibrosis patients, Geron's imetelstat generated a clinical response defined in part by an observed improvement on bone marrow damage among about 21% of patients. Furthermore, 12% experienced a complete remission defined by complete reversal of damage. GLYC (T/$11-21)...leukemia drug ...rocket because of FDA breakthrough designation... According to GlycoMimetics, data announced earlier this month showed high response rates, tolerability, and the first-ever clinical evidence supporting the mechanism of action for GM-1271. It works by disrupting a molecule called E-selectin, which allows circulating cancer cells to attach to healthy cells. The process plays a key role in metastasis and AKL, a cancer of the blood and bone marrow, in which cancer cells interrupt the production of healthy blood cells. Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. ****GTHX (T/$30) ... engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. HALO (T/$7) Halozyme Therapeutics, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. ***IDRA 1.57 low (T/$4-8) cancer rare disease.. *****IMDZ (T/$16-18) ... a prime-boost vaccine approach against NY-ESO-1-expressing tumors, designed to generate an integrated, anti-NY-ESO-1 immune response in vivo via a targeted, specific interaction with dendritic cells, a mechanism of action Immune Design believes differs from traditional cancer vaccines. IMGN (T/$9-11) ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML *****IMNP
() Immune Pharmaceuticals findings showing that treatment of mice with Ceplene® efficiently reduces the formation of lung melanoma metastases. Using genetically modified mice, the authors also show that the beneficial effect of treatment with Ceplene® in reducing metastasis was likely explained by its inhibitory effect on NOX2, which is an enzyme expressed by myeloid blood cells. In the article, the investigators additionally report that combination immunotherapy with Ceplene® and interleukin-15 (IL-15) reduced melanoma metastasis by over 70%, an incremental effect over Ceplene alone or IL-15 alone. **INFI (T/$2H) treatment of blood cancers...
****ITUS .... "ITUS's unique liquid biopsy approach utilizes flow cytometry to measure the presence and characteristics of certain circulating immune cells. We then use Artificial Intelligence to analyze the data in a manner that enables us to identify tumor bearing patients. The test utilizes a simple blood draw from the patient. To date, our technology has demonstrated its ability to identify 15 cancer types including breast, prostate, colon, lung, pancreatic, and others. Because we are measuring subtle changes in circulating immune cells, it is not surprising that our technology appears to work on multiple cancer types, and we expect the technology will eventually be able to identify all cancer types. ITUS is performing additional tests including the evaluation of benign conditions which may exist in patients but are not malignant tumors."
KPTI ....09/20/17... PHASE 2 SUCCESS... “Liposarcomas are difficult to treat solid tumors that arise from the body’s fat tissue cells or their precursors,” said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. “Dedifferentiated liposarcoma is an aggressive form of the disease that is resistant to both standard chemotherapy and radiation and has a particularly high rate of recurrence following surgery. Most patients who progress following surgery will ultimately succumb to their disease, highlighting the significant unmet need that exists for novel therapies. The FDA has confirmed their acceptance of the proposed Phase 3 SEAL study design, including the PFS primary endpoint, and agreed that positive results from this study could support regulatory approval in this patient population.”
***IOVA (T/11-16) focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer KMPH
(T/$8) ADHD IOVA
(T/$13) KPTI (T/$15) Karyopharm's blood cancer hopeful. Selinexor is a first-in-class oral treatment slated for a large, late-stage combination study with multiple myeloma patients also receiving Velcade and standard chemo. If successful, results from the pivotal trial could eventually support the company's first New Drug Application, KURA
(T/$13) Developing in-licensed protein inhibitors for solid tumors and blood cancers. United States Patent and Trademark Office has issued a patent protecting the company's lead product candidate, tipifarnib, which is currently being studied in multiple Phase 2 clinical trials. Tipifarnib is an inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development, and is under investigation in multiple ongoing clinical trials. Tipifarnib has demonstrated encouraging preclinical and clinical activity, including durable partial responses, in an ongoing Phase 2 clinical trial in patients with HRAS mutant SCCHN. Additional information about this clinical trial can be found at clinicaltrials.gov. MGNX
(T/$26) MRUS in Phase 1/2 across three different indications — breast, colorectal and ovarian cancer — and based on data NAVB... Lymphoseek, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. *OBMP () Bio cancer vaccines... **OMED 3.20 low (T/$6) (fv $6.68)OncoMed Pharm...anti-cancer stem cell (CSC) and immuno-oncology therapeutics... Lung...Ovarian...Colon... OPK
(T/$11) Prostate cancer test...Human groth hormone... PGNX
(T/$12-15) Progenics Pharmaceuticals ...pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic. PBMD
(T/$5-7) Prima BioMed Ltd core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. SRNE
(T/$7-16-20) Sorrento Therapeutics... focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy. primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy. TROV (T/$4) Myeliod Leukemia ***SNDX (T$/20-27) ...pipeline of combination therapies in multiple cancer indications. Our lead candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers. ...(
Motley Fool...Despite the breakout success of checkpoint inhibitor antibodies in fighting a host of cancers
, these highly touted treatments do have a serious drawback -- response rates vary widely across tumor types. In a best case, advanced Hodgkin lymphoma patients receiving an anti-PD-1 checkpoint inhibitor have exhibited response rates as high as 60%. More typical response rates for this new class of treatment, though, have hovered around 20% in head and neck, lung, and bladder cancers.
That's where a company like Syndax Pharmaceuticals and its oral, small-molecule product candidate entinostat could make a big splash. The treatment is part of the third wave of immuno-oncology drugs (behind checkpoint inhibitors and cell-based therapies). Entinostat's job, if you will, is to block the action of immune suppressor cells -- known as myeloid-derived suppressor cells -- as well as regulatory T cells, when used in combination with a checkpoint inhibitor. If it succeeds, it will act synergistically with checkpoint inhibitor antibodies to produce a more robust immune response. At present, Syndax is evaluating entinostat in several clinical trials for breast cancer, non-small-cell lung cancer, advanced melanoma, and ovarian cancer. While it's arguably unreasonable to assume that the drug will prove useful in the majority of these indications (based on the poor track record of experimental cancer therapies in general), it shouldn't need to hit on more than one of these conditions to become a major value driver for a company with a market cap of only $304 million. And if a positive readout happens to come through in the high-value breast cancer market, this developmental biotech should prove to be a true hidden gem. URGN
(T/$28) Urogen Pharma is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. ...
VRML (T/$1.75) Varmillion bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women in the United States. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The company's products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor ZYME
(T/19) Zymeworks lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems. Pain Relief The potential market is huge. Over 200 million prescriptions are filled each year for drugs to manage pain outside of the hospital setting. Another 100 million prescriptions are filled annually for managing chronic pain. Over 20 million Americans take prescription drugs for treating uremic pruritus. 07/31 FDA/
08/03 earnings ACRX ACRX (T/$7)Zalviso Phase 3 trial ..."Since its launch in the first half of 2016, ZALVISO's patient-focused design has garnered positive feedback from patients, who appreciate taking control over their pain, as well as from physicians who are pleased with the product's usability and the desired level of analgesia delivered. BDSI
(T/$4-5) BioDelivery Sciences International... Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology. ***CARA (T/$21-32) ... Share dilution April... 5 million shares at $18...The company's most advanced product is CR845, an injectable kappa opioid receptor agonist intended for the treatment of acute pain. What makes CR845 special is that unlike traditional pain relief medications (opioids), CR845 targets the "kappa" receptor rather than the "mu" receptor. This means that the drug provides pain relief without many of the side effects associated with traditional opioid therapies such as nausea, vomiting, and respiratory depression. Moreover, because CR845 only acts in the periphery (it cannot enter the brain and spinal cord), the drug is unable to create any of the "euphoric" side effects of traditional opioid pain medications. In layman's terms, this means that CR845 has the potential to provide a non-addictive form of pain relief with fewer of the side effects associated with traditional therapy....its drug development pipeline isn't entirely devoted to cannabinoid or endocannabinoid-mimetic drugs. In fact, Cara Therapeutics, which is entirely clinical-stage at this point, is almost exclusively focused on developing CR845, a kappa opioid receptor agonist (KORA) that has nothing to do with cannabis. Cara's ties to cannabis relate to its preclinical research involving CR701, a cannabinoid receptor agonist that's designed to treat chronic pain. Considering that there were no documented overdose-related deaths from marijuana in 2016, compared to over 20,000 prescription opioid overdose deaths in 2015, there's a clear push to consider CB agonists as a possible solution to chronic pain. In rodent models, CR701 produced "hyperalgesia (sensitization of nerve ending to panful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions."
IMSYS (T/$14) sublingual fentanyl spray
CORI (T/$10-16) As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R) (7/11/2017) KMPH
(T/$7-13) lead product candidates are an extended release d-threo-methylphenidate product for the treatment of ADHD; an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. ...also involved in developing a prodrug of hydromorphone for the management of pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.
****TRVN (T/$8-9-10-14) intends to commercialize therapeutics for G protein coupled receptors. The company's central nervous system product pipeline includes Oliceridine, a small molecule G protein biased ligand, which is in Phase III clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment refractory migraine. In addition, the company develops cardiovascular programs, such a TRV027, a peptide beta-arrestin biased ligand that targets the angiotensin II type 1 receptor and is in Phase IIb clinical trials for the treatment of acute heart failure in combination with standard diuretic therapy. ... ****REPH... (T/$12-21 )Recro Pharma, pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain. *****PTIE ...(7?) Pain Therapeutics a
safer oxycontin = FDA has provided the company with a clear path for Remoxy ER approval if the company completes two studies, one clinical and the other non-clinical. The company expects to successfully complete both clinical studies in 2017 and has the resources to do so. The company ended 2016 with $18.7M in cash and burns $3M/quarter. EGLT... NKTR... INSY
(T/$16-22)...see marijuana stocks near bottom of this page...the potential applications for dronabinol, including sleep apnea and opioid dependency, could catapult this drug to annual sales in the billions. **IPCI (T/) pharmaceutical company,...patent on a way to control overdose of prescribed narcotic medications. KALV (T/$10) Phase III clinical trial designed to provide rapid sustained relief from pain associated with osteoarthritis... RDHL ...STML...blood cancers... AST spinal cord injuries and cancer ... *****FLXN
(T/$38) Flexion Therapeutics ...likely approval of the company's first commercial compound by the FDA on the October 6th PDUFA date. It should be approved for the treatment of osterarthritis of the knee and is in trials for two other indications. A recent study showed that Zilretta at a cost of $500 per treatment "had a greater impact on quality-of-life measures than conventional care, diclofenac (NSAID) and HA treatment". This is already a large market and growing as the developed world ages and as society grows more obese. Zika virus http://www.buyupside.com/sample_portfolios/ebola.php *BCRX (T/$6H)... XON(T$40)... INO (T/$13) biopharmaceutical, zika virus, Ebola...bladder cancer SNY...drug manufactures ***Medical/Robotics/Equip The robotic-surgery space is forecast to explode at a compound annual growth rate of more than 22% over the next five years, making it one of the fastest-growing industries in the healthcare sector. Nov. 1,2016 Fool.com *****AEMD medical device company ...Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has received an Expedited Access Pathway (EAP) designation from the United States Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier® to treat life-threatening viruses. The FDA EAP program was established to facilitate more rapid patient access to breakthrough technologies with the potential to address life threatening disease conditions for which no approved or cleared treatment alternatives exist. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer. https://finance.yahoo.com/news/aethlon-medical-receives-expedited-access-113000571.html ANGO
(T/$11) ...medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system, a non-surgical alternative for the treatment of overweight and obese adults; and OverStitch, an endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through an Olympus dual-channel flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. ATEC
(T/$4) products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar, and intervertebral regions of the spine, as well as covers various spinal disorders and surgical procedures. The company offers cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate, and Pegasus Anchored Cervical Interbody system. It also provides thoracolumbar fixation products, such as Arsenal Degenerative System, Arsenal CBx Cortical Bone Fixation System, Zodiac Degenerative Spinal Fixation System, Zodiac Deformity Spinal Fixation System, and OsseoScrew Spinal Fixation System. In addition, the company offers spinal spacers comprising Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer; and MIS Products consisting of Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System. Further, it offers biologics, such as Neocore Osteoconductive Matrix, a synthetic scaffold for the regeneration of bone. ****ATRS
(T/$4-5) Antares Pharma ompany develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. BLFS
(T/$6) joint replacement ****CHEK
(T/$6) Check-Cap Ltd ... development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening... Colorectal cancer is the second leading cause of cancer death in the U.S., with an estimated 135,000 diagnoses and 50,000 deaths in 2017. Despite compelling evidence that screening can detect colorectal cancer and precancerous polyps, nearly one-third of the recommended adult population has never been screened. *****CTSO (T/$7-10-13) CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, ...engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
CVR Medical (TSX:CVM.V; OTC:CRRVF), and its potentially life-saving device is the Carotid Stenotic Scan (CSS)--a technology designed to detect stenosis within arteries, or Ischemia, which is the leading indicator of strokes.Of the 15 million people who suffer stroke every year, some 6 million are killed, while 5 million are rendered permanently disabled, according to the World Heart Foundation. But there has been no cost-effective way to screen for Ischemia. So, when a biotech company offers a potential solution to help prevent the second-leading cause of death in the world--and then releases positive preliminary clinical trial results, investors listen. Now it’s hoping to charge out of the gate and take the market by storm once it manages to gain FDA market clearance.
In the meantime, the catalysts are really lining up:
On 7 September, CVR released updated results from its preliminary clinical trial that showed forward progress for the medical device, which we’ve been watching closely for some time. You can view the results from Thomas Jefferson University here.
And a few weeks prior, they announced another landmark achievement when they signed a letter of intent to manufacture the CSS. The deal gives CVR state-of-the-art manufacturing capabilities with Canon Virginia, Inc (CVI). This would give CVR immediate scalability, and also adds to its credibility: It’s not the first manufacturing deal the company has sealed.Our researchers are keeping a close eye on CVR Medical Corp. because we think this is the turning point. Here’s why:
• It’s had two fresh catalysts in three weeks in an industry that is all about validation
• It’s developing a device that meets critical demand in terms of helping to prevent one of the most debilitating and deadly diseases of our time
• It’s developing a medical device that actually makes sense to the market
• It’s been doing it quietly, without blockbuster hype, and instead painstakingly going for real validation, making it the real deal.
Here are 5 reasons to keep a close eye on CVR Medical (TSX:CVM.V; OTC:CRRVF) in the coming weeks and months:
#1 Catalysts are Lining Up, and News Flow is Gaining Momentum
First, one way to look at the CSS is to think about what 3D seismic imagery did for super quick discoveries in the oil and gas industry. This is exactly what CVR’s sensory system could do for the medical industry in terms of detecting critical stroke symptoms.
This is how it works:
CVR’s Carotid Stenotic Scan (CSS) is a tool to detect blockage within the Carotid Arteries, potentially offering patients and caregivers a device for early detection in a quick and repeatable manner. CVRS (T/$3) Corindus Vascular Robotics, designs, manufactures, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. Its CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise, robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. ELGX (T/5) Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions, which attach to the main body of its EVAR device, allowing physicians to customize it to fit the patient's anatomy; and accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, inflation devices, and snares.
http://oilprice.com/Energy/Energy-General/Could-This-Be-The-Biggest-Biotech-Breakthrough-Of-The-Year.html *EDAP High Intensity Focused Ultrasound (HIFU)(kidney stones, and Urology Devices and Services. AMDA(T/$1.50) ISRG Intuitive Surgical ... ****ERBA diagnostic test kits automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing... EYES (T/$5) bionic eye...WE Are Borg...you will be assimilated... GNMK
(T/$14-17) ....Company provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable testEYES (T/$5) bionic eye...WE Are Borg...you will be assimilated...cartridges. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test. The company also provides ePlex instrument and RP panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results without any additional steps. HTGM (T/$6) 09/20 2 PATENTS...https://finance.yahoo.com/news/htg-announces-issuance-two-method-120000387.html
... instruments molecular profiling applications ...mRNA biomarkers... ICAD (T/$11) IVTY
LMAT () LaMairtre Vascular -- a medical device maker that is profitable, growing quickly, debt-free, and has been a multibagger since its IPO in 2007.
As its name suggests, LaMaitre is a provider of medical products that are primarily used by vascular surgeons
. The company's strategy is to buy or build niche products that can be used to treat peripheral vascular disease (PVD) -- a blood circulation disorder that affects more than 200 million people worldwide. The disease is caused by the buildup of fatty deposits inside blood vessels that can restrict blood flow, which can lead to a range negative outcomes including organ damage, loss of limbs, and even death.
One way to treat PVD is through elective surgery, which is where LaMaitre comes into the picture. The company sells 15 different lines of products used during vascular surgery -- think shunts, grafts, patches, and catheters. What most of its products have in common is that they target niche opportunities. In fact, 97% of the company's revenue comes from segments that rack up less than $125 million in total annual sales. Markets that small typically don't interest the big boys much, which helps to limit LaMaitre's competition, allowing it to capture market share more easily, and to push through regular price increases.
Looking ahead, investors should feel confident that LaMaitre can continue to grow its top line as it adds more sales reps, expands geographically, and makes occasional tuck-in acquisitions. When those factors are combined with its steady margin improvement, planned price increases, and stock buybacks, the company looks to stand a good chance at continuing to deliver on its stated targets of 10% revenue growth and 20% operating income growth annually. If it does, I could easily see its stock continuing to outperform from here. That makes LaMaitre a hidden gem that all growth-focused healthcare investors should get to know. Motley Fool *****MBOT MicroBot Medical... U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key technology patent. The Patent App. No. 14/348,610, covers a device for the prevention of shunt stenosis. Micro-robotic technologies... Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH); and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. **MZOR (T/30H)...Mazor Robotics http://www.fool.com/investing/general/2016/05/28/does-mazor-robotics-deal-with-medtronic-make-it-2.aspx
NVCR ...wearable electric field device for treating glioblastoma brain cancer...proprietary therapy called TTFields for the treatment of solid tumor cancers. NovoCure believes it will establish TTFields as an important new treatment modality for a variety of solid cancer tumors by increasing survival without increasing side effects when used in combination with other modalities. NUVA () Minimally invasive spinal surgery MDT... JNJ...PHG...SYK...ZBH
PAVM (T/$10) The company's product pipeline includes NextFlo, a disposable infusion pump; PortIO, a long-term implantable vascular access device; Caldus, a disposable tissue ablation device; CarpX, a percutaneous device to treat carpal tunnel syndrome; and NextCath, a self-anchoring short-term catheter. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. ******TRXC (T/$2) commercialization of surgical robotic systems company has moved it focus from surgibot to senhance ... http://www.bizjournals.com/triangle/news/2017/06/16/eyeing-fda-approval-transenterix-makes-first.html?ana=yahoo&yptr=yahoo TITXF () robotic surgical system for application in minimally invasive surgery... STXS robotic systems and instruments for the treatment of abnormal heart rhythms...“The Niobe system is perhaps the most revolutionary invention in the field of cardiac ablation, enabling remote anatomic mapping of electrical currents and eradication of difficult-to-reach arrhythmias with unparalleled safety and pinpoint precision,” said Tung. “Our acquisition of Stereotaxis’ latest generation remote magnetic navigation platform will enhance a highly respected electrophysiology (EP) program that is regarded as a global leader in ablation therapy, research and education, especially in the treatment of ventricular tachycardia (VT), and will greatly improve patients’ lives.” NVIV
() ...InVivo Therapeutics... focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. NVTR (T/$10H) CyBorg technology...neuroscience... ***MLSS
(T/$4) STA Single Tooth Anesthesia Instrument, a computer-controlled local anesthesia delivery instrument that incorporates the pressure feedback elements of its patented CompuFlo technology, which allows dentists to administer injections into the periodontal ligament space; and CompuDent, a computer-controlled local anesthetic delivery instrument that provides painless injections for various routine dental treatments, including root canals, crowns, fillings, and cleanings. Its products also comprise CompuMed, a computer-controlled injection instrument for use in various applications, such as colorectal surgery, podiatry, dermatology, cosmetic surgery, hair restoration surgery, nasal and sinus surgery, orthopedics, and others. In addition, the company provides The Wand, a hand piece that allows bi-directional rotation during injection, which prevents needle deflection that occurs with a traditional syringe. RWLK RWLKRobotics exoskeleton ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. www.rewalk.com EKSO (T/$5)...COMPETITION...Exoskeleton
.I-Hub Board https://investorshub.advfn.com/ReWalk-Robotics-Ltd-RWLK-28903/
SIEN (T/$14-15) Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons and patients in the United States. The company offers a portfolio of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; and breast tissue expanders. It also provides body contouring and other implants, including gluteal, pectoral, calf, facial, and nasal implants, as well as nasal stents; silicone elastomer oval carving blocks to treat deformity caused by trauma, congenital and other deformities, or cancer therapy; scar management specialty products under the Medgel brand to treat various types of scars; breast sizers to identify the style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. SPNE
(T/$15) SeaSpine Holdings
...focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and Internationally. The company provides orthobiologics and spinal fusion hardware solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers its orthobiologics products in various forms, such as putties, pastes, and strips. Its spinal fusion hardware products comprise products for spinal fusion in minimally invasive surgery, complex spine, deformity, and degenerative procedures throughout the lumbar, thoracic, and cervical regions of the spine. TROV (T/$4) molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
VIVE (T/$11) Viveve, Inc., designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal laxity. It provides Viveve system, a non-invasive treatment for vaginal laxity that occurs during natural childbirth. XTNT
(T/$1.50) biomaterial products include OsteoSponge provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC to fill bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company provides BacFast HD facet stabilization dowels; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; hMatrix dermal scaffold, an acellular matrix made from donated human dermal tissue that is used to replace a patient's damaged tissue; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. Other Medical AEZS
(T/$4) 07/19 FDA approval for Adult Growth Hormone ALQA
(T/$1.5) AMDA (T/$2-5 )biomaterials, Valeo silicon nitride spinal fusion devices.(additional shares/dilution Jan 2017 $0.51... ARDX (T/$12) lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. ARNA (T/$5) ulcerative colitis 08/09AMC ATHX ($7-9)... focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. ATRA
(T/$3) address dermatology and women's health markets. The company offers an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris. The company is also developing BPX02, an injectable product for aesthetic dermatology applications. CLDX biotech... CSLT (T/$5.50) ...operates a health benefits platform in the United States. ***CYTR() CytRx Corp...Soft tissue sarcoma is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. It can arise anywhere in the body at any age. STS remains a high unmet medical need because of the difficulty in treating the more than 50 types of this aggressive cancer. According to the American Cancer Society, in 2016 more than 12,300 new cases were diagnosed in the U.S. and approximately 5,000 Americans died from this disease. In addition, approximately 40,000 new cases and 13,000 deaths in the U.S. and Europe are part of a growing underserved market. Recently, the company announced the U.S. Food and Drug Administration reached an agreement with CytRx on preparations for a New Drug Application submission for aldoxorubicin in soft tissue sarcomas. 2017 American Society of Clinical Oncology (ASCO) Annual Meeting...the data presented at ASCO this year demonstrate that, unlike any other drugs in this class, aldoxorubicin can be dosed continuously with minimal to no cardiotoxicity," commented Sant Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, California, and Principal Investigator for the Phase 3 trial. https://finviz.com/chart.ashx?t=CYTR&ty=c&ta=1&p=d&s=l EXEL Exelixis biotech... EYEG
(T/$6) EyeGate is developing products using CMHA-S, a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. EGP-437, EyeGate’s other product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System. GLMD (T/$14) Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is developing Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It is also evaluating Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. ***HLTH (T/$2.50)...outpatient surgery facilities...
MPW (T/$15) Medical Properties RIET NEOS Neos Therapeutics ADHA drugADHA drug approved June 19th 2017...... ... PSDV
(T/$5) chronic eye diseases KURA
(T/$16) ...protein inhibitors for solid tumors and blood cancers...
(T/$10) ...markets prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue, skincare, and animal healthcare markets in the United States, Latin America, Europe, and rest of the world. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of pathogens that cause disease, including viruses, fungi, spores, and bacteria, such as antibiotic-resistant strains. The company's Microcyn has received fourteen 510(k) clearances for use as a medical device in tissue care management consisting of acute and chronic wounds, and in dermatology applications.
TXMD (T/$10-15) BIG short interest 08/25...$5.93)
...manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. XTNT
(T/$1.50) OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC to fill bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company also provides BacFast HD facet stabilization dowels; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; hMatrix dermal scaffold, an acellular matrix made from donated human dermal tissue that is used to replace a patient's damaged tissue RIGL
(T/$15H-22H)...FDA Breakout designation for IgA nephrophy IMGN
(T/$6) Alt-Energy ***ARTX artx (T/$5)defense and security products sells rechargeable and primary batteries, and smart chargers to the military... CPST
($1-2) Capstone Turbine markets and services microturbine technology solutions for use in stationary distributed power generation applications, including cogeneration (combined heat and power), integrated combined heat and power (ICHP), and combined cooling, heat and power (CCHP), renewable energy, natural resources and critical power supply. The Company's microturbines are used as battery charging generators for hybrid electric vehicle applications. Capstone offers micro turbines for commercial, industrial and utility users with product offerings ranging from 30 kilowatts (kW) to 1 megawatt in electric power output.
EFOI (T/$6) engaged in developing and selling of light-emitting diode (LED) lighting products for military maritime market, and general commercial and industrial markets. It produces, sources and/or markets a range of lighting technologies to serve its primary end markets. It offers military maritime products, such as Military Intellitube, military globe lights and military berth light to serve the United States navy and allied foreign navies. It offers commercial products, such as direct-wire tubular LED (TLED) replacements for linear fluorescent lamps, LED dock lights, low-bay and high-bay lighting for high-intensity discharge applications and LED retrofit kits to serve general commercial and industrial markets. TGEN
(T/$6) Tecogen Inc. designs, manufactures, sells, and services systems that produce electricity, hot water, and air conditioning for commercial installations and buildings, and industrial processes. The company offers cogeneration units that supply electricity and hot water; chillers that provide air-conditioning and hot water; and high-efficiency water heaters. Its products include InVerde, a 100-kilowatt combined heat and power system that primarily provides electricity and hot water; TECOGEN cogeneration system, which produces approximately 500,000 Btu/hr of hot water; TECOCHILL natural gas engine-driven chillers; and Ilios high-efficiency water heaters. The company also provides long-term maintenance contracts, parts sales, and installation services. Tecogen Inc. offers its products and services for hospitals and nursing homes, colleges and universities, health clubs and spas, hotels and motels, office and retail buildings, food and beverage processors, multi-unit residential buildings, laundries, ice rinks, swimming pools, factories, municipal buildings, and military installations. AMRS
(T/$15)...Amyris, Inc The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. ***ERII (T/$16-21)energy recovery devices, turbochargers for water desalination/makes equipment for oilfield that makes fracking more efficient .. . *AMSC (T/$10-11) now in doubt) wind turbine systems... RVLT (T/$?) sells light emitting diode (LED) lighting solutions... MNGA (T/$) converts liquid waste into hydrogen based fuels... *CWST (T/$13H)water treatment... *HCCI (T/16H) oil clean up parts cleaning... ***MXWL (ultra Capacitors) .. energy storage and power delivery products, ultra-capacitor cells... CDTI CDTI
(T/$4) diesel emissions control systems...
***OPTT (5.3 million share dilution Apr 27)...ocean wave electricity... VTNR recycle industrial waste... FF biofuel SPCL (Google finance)...Solaris Power Cells, Inc. is a developmental stage diversified "Green" Energy Storage manufacturer offering residential and commercial users turnkey, renewable energy storage solutions (ESS). Solaris manufactures the Solaris PESA™ "Passive Electron Storage Array"™, for limited use electric vehicles such as golf cars and Mega Energy Storage Systems. (ESS) The Solaris PESA™ is a 100% lead-free, solid-state storage (ESS) solution that makes renewable energy greener and better by allowing applications to utilize more of the energy generated. The Solaris Power Cell™ is capable of providing energy storage to applications normally reliant and equipped with highly toxic lead acid, nickel metal hydride or lithium-ion batteries. CTRL.
.(T/$22)...smart home... ECR
(T/$3)... GEVO (T/$12) Graphene... NGPHF NGPHF Northern Graphite.. *GPHOF .....***FCSMF... *ZENYF .... FUEL CELL Ceramic/Solid Oxide Fuel Cells €*****BLDP (T/$3.5-6)...09/13 2017 Ballard Power Systems Inc. surged the most in more than a year after announcing it has developed a lightweight fuel cell that uses less platinum. https://finance.yahoo.com/news/ballard-surges-fuel-cell-uses-155901753.html Sept. 13,2017 Ballard Power Systems has sales and partnerships with companies who make buses, trains, trucks, forklifts, drone makers, and even major automakers. It has a diverse pipeline of products as a result, despite the fact that over half of its revenue last year came from just three customers. (Motley Fool) €***PLUG (T/$2h-3)... Plug Power gets all of the media's attention for its huge supply agreements with Walmart and Amazon. Plug Power's business is becoming increasingly reliant on Walmart, which accounted for 34.1% of its business in 2016. As the Amazon deal ramps, the two retailers will likely account for well over half of Plug Power's revenue. That's not a diverse customer base, and since forklifts are the main product being served, it's not a diverse set of products Plug Power is supplying. €***FCEL (T/$2)... Specializing in stationary fuel cell power plants for electricity generation. €****HYGS .HYGS Hydrogenics Hydrogenics Corporation, hydrogen generation products based on water electrolysis technology; and fuel cell products based on proton exchange membrane technology. It operates in two segments, OnSite Generation and Power Systems. The OnSite Generation segment develops products for industrial gas, hydrogen fueling, and renewable energy storage markets. It offers HySTAT Hydrogen Stations that supply on-site hydrogen for various hydrogen applications, including vehicle fueling, distributed power, and various industrial processes; and provides spare parts and services. This segment sells its products to original equipment manufacturers (OEMs), merchant gas companies, end users, and oil and gas companies, as well as to electric power utilities. The Power Systems segment develops products for energy storage, stationary, and motive power applications. This segment offers HyPM fuel cell products comprising HyPM fuel cell power modules that produce direct current (DC) power in standard outputs of 2.5, 5, 8, 12, 16, 30, 90, 120, and 200 kW; and HyPX Fuel Cell Power Pack, which includes a standard HyPM power module integrated with hydrogen storage tanks and ultracapacitors to provide higher power in short bursts. Its HyPM fuel cell products also consist of integrated fuel cell systems that are used for portable and stationary applications, including portable and auxiliary power units for military applications, and DC or DC backup power system for cellular tower sites, as well as provides engineering development services for new or custom products. CEFLF ...Ceramic Fuel Cell... CPWHF... NPWZ... HFCO... SSMFF... ITMPF... EVOMF
Energy Storage companies - A new and developing area, so not easy to pick the winners here. Certainly the major battery manufacturers and lithium miners discussed above can benefit. Numerous others to choose from include...
****ENPH Enphase Energy (T/$4) The company's semiconductor-based microinverter system converts direct current electricity to alternating current (AC) electricity at the individual solar module level. The Enphase AC Battery is a key component of the Enphase Home Energy Solution, the industry's first and only truly integrated offering that combines solar generation, energy control, and storage, and provides homeowners the unique ability to manage their solar and storage together in an integrated fashion. Advanced Microgrid Solutions (private ), Fronius (private), Imergy (private), Redflow (ASX:RFX), AES Corp. (NYSE:AES), NEC (OTC:NIPNF), Sharp (OTCPK:SHCAY), Younicos (private, interest held by First Solar), Southern California Edison (SCE), General Electric (NYSE:GE), EnerSys (NYSE:ENS), Johnson Controls (NYSE:JCI), Sony (NYSE:SNE), Sonnen (private) and Origin Energy (NASDAQ:ORG). Electrovaya (EFL.TO) could well be the little company that could. Developer and manufacturer of portable Lithium-ion battery power solutions for the automotive, power grid, medical and mobile device sectors. The company is based in Mississauga, Ontario, Canada ZINC zinc-based batteries appeal is that they could pack TWICE the power as their lithium-based cousins. ZZZOF ... GLNCY... HL... HBM... MUX... AG... VEDL (India) Colbalt ECSIF eCobalt Solutions... Cobalt metal ... http://www.infomine.com/investment/metal-prices/cobalt/ https://seekingalpha.com/article/4066102-ecobalt-solutions-getting-u-s-equity-exposure-cobalt-metal-revolution Cobalt metal is in high demand due to growth in the electric vehicle ("EV") market, which uses lithium-ion batteries to power these vehicles (cobalt being a main component). In conjunction, its growing supply deficit is leading the price of the commodity higher. Macquarie Research projected a supply deficit of 885 tonnes in 2018, 3,205 in 2019, and 5,340 in 2020. That comes to a supply deficit increase of 6x in just two years. For large-cap tech companies and automakers looking to produce electric vehicles, the need for cobalt has become increasingly clear given its role in the lithium-ion battery mix. The metal constitutes a little over one-third of a modern lithium-ion battery's composition (and greater than the amount of lithium used itself). FTSSF ...Fist Colbalt... How the competition is doing - Larger mining companies also have cobalt operations ongoing, including Freeport-McMoRan (NYSE:FCX) (T/$12-16), Katanga Mining (OTCPK:KATFF), Glencore (GLCNF), Fortune Minerals (OTCQX:FTMDF), Barra Resources (OTC:BRCSF), Tiger Resources (OTC:TRSDF), Lundin Mining (LUNMF), and Cruz Cobalt Corp. (OTCPK:BKTPF). Solar....http://finance.yahoo.com/news/why-solar-energy-explosive-potential-202908604.html CAFD (T/$15) November 30, 2015, it owned interests in six utility-scale solar energy projects, two commercial and industrial solar energy projects, and a portfolio of approximately 5,900 residential solar installations with a total capacity of 432 megawatts. IPWR
AES (T/$12) AES Corp... Utility-scale energy storage is expected to surpass 1.6 gigawatts by 2020, edging out the old grid system and making it that much easier to integrate more renewable capacity — once the tech catches up! San Diego Gas & Electric chose a battery design by AES Corp. (NYSE: AES) to begin replacing one of its largest natural gas peaking plants with as much as 300 megawatts of battery storage. The company will also be upgrading the existing plant, but it notes that the end goal is to replace it with renewables later on. Southern California Edison has also contracted Tesla, in a move that should surprise no one by now, to continue building onto its existing 80-megawatt energy storage project in Mira Loma. The system is already online as of this year and can cover peak energy demand for as many as 15,000 California homes. Right now, it’s the biggest lithium battery station operating in the U.S. As it stands, electric cars are still set to be the biggest source of growth in lithium batteries in coming years, but that view could shift if this trend gains traction...
MXWL (T/$6) Maxwell Technologies, Inc. develops, manufactures, and markets energy storage and power delivery products worldwide. The company offers ultra-capacitor cells, and multi-cell packs and modules, which provide energy storage and power delivery solutions for applications in various industries, including bus, rail, and truck in transportation; grid energy storage; and renewable wind energy solutions. It also provides lithium-ion capacitors, which are energy storage devices designed to address various applications in the rail, grid, and industrial markets where energy density and weight are differentiating factors. In addition, the company offers CONDIS high-voltage capacitors, such as grading and coupling capacitors, and electric voltage transformers that are used to ensure the safety and reliability of electric utility infrastructure and other applications involving transport, distribution, and measurement of high-voltage electrical energy.
MXWL (T/$6-7) he company offers ultra-capacitor cells, and multi-cell packs and modules, which provide energy storage and power delivery solutions for applications in various industries, including bus, rail, and truck in transportation; grid energy storage; and renewable wind energy solutions. It also provides lithium-ion capacitors, which are energy storage devices designed to address various applications in the rail, grid, and industrial markets where energy density and weight are differentiating factors. In addition, the company offers CONDIS high-voltage capacitors, such as grading and coupling capacitors, and electric voltage transformers that are used to ensure the safety and reliability of electric utility infrastructure and other applications involving transport, distribution, and measurement of high-voltage electrical energy.
LIT Lithium research
Beware of looming electricity and lithium shortages. When Bloomberg did its analysis it predicted, “Electricity consumption from EVs will grow to 1,800 terawatt-hours in 2040, or 5 percent of global power demand, from 6 terawatt-hours in 2016”. This is a staggering 3,000 percent increase. Where will it come from? Better not be coal or possibly even natural gas. At a conference held April 3 in Calgary sponsored by ARC Energy Research Institute (AERI) a representative of Bruce Power, the Ontario nuclear electricity generator, said to economically reduce carbon emissions recharging EVs only made sense at night, not during peak load hours. If everybody drove their EVs to work and tried to plug in at the office it would overload the system. Meanwhile, there is speculation whether the world has enough lithium to build all the batteries skyrocketing EV growth would ensure. One analyst has predicted lithium shortages as soon as 2023 and have already delayed Tesla’s output. The solution, which is not all bad for the oil industry, is dual fuel whereby the battery is smaller, the lithium required per vehicle is lower, and mobility is augmented by a smaller ICE using good old-fashioned gasoline. http://oilprice.com/Alternative-Energy/Renewable-Energy/Electric-Vehicles-No-Threat-To-Oil-Prices-Anytime-Soon.html
Related automaker stocks: GELYF, OTCPK:GELYY, OTCPK:BYDDY, OTCPK:BYDDF, KNDI, OTCPK:DNFGY, OTCPK:DNFGF, OTCPK:DDAIF, OTCPK:VLKAY, OTCPK:BMWYY, GM, OTCPK:GNZUF, OTCPK:GNZUY, TSLA, F, OTCPK:NSANY, TM, TTM, HMC, OTCPK:MZDAY, OTCPK:PEUGF, OTCPK:PUGOY, OTC:PUGOF, OTC:RNSDF, OTCPK:RNLSY, MBLY, NVDA, ALV, DLPH.
New Battery better than Lithium...John Goodenough, the 94-year-old father of the lithium-ion battery
(T/$4) Ideal Power Inc. develops power conversion solutions with a focus on commercial and industrial grid storage, combined solar and storage, and microgrid applications. The company offers 30kW battery converters for the commercial and industrial grid-tied distributed energy storage market; 30kW grid-resilient alternating current (AC) - direct current (DC) power conversion system (PCS) with two-ports, as well as 30kW grid-resilient AC-DC-DC multi-port model; and 125kW grid-resilient AC-DC PCS. It also focuses on licensing its proprietary power conversion Power Packet Switching Architecture to original equipment manufacturers. RGSE ....02/06 ...$11million dilution and price goes UP... RUN...solar financer and installer...
SEDG (T/$25) SolarEdge Technologies designs, develops, and sells direct current (DC) optimized inverter systems for solar photovoltaic (PV) installations in Israel, Europe, the United States, and internationally. The company's DC optimized inverter systems include power optimizers, inverters, and cloud-based software. SPWR
****SUNW () earnings growth next year...Sunworks, Company is focused on the design, installation and management of solar power systems for commercial, agricultural, residential and municipal customers. It is a solar systems provider in the western United States, delivering over 2.5 kilowatts to multi-megawatts commercial systems. It provides energy solutions and services to its customers, including project management and installation support, solar energy performance assessments, solutions consultations, materials and equipment procurement support, as well as rebates and incentives management. It is a solar installation and consulting company that offers financing and leasing options. It offers Property Assessed Clean Energy (PACE) financing program for financing home solar energy systems. It provides various system offering solutions, such as roof mounted solar systems, dual-axis trackers, ground mounted systems and tilted single axis trackers WNDW Solar Window Tech. CandleGlance PBW...Clean Energy etf...DQ,TSLA,SQM,OLED,GLBL,BGC,ORA,PWR,HXL... ***AMSC (T/$7) Wind and electrical grid... NRG...energy utility
Is thorium really that safe?
Thorium ...storage of spent rods is still an issue same as with uranium
Uranium Bull Market
NLR...CandleGlance Uranium... URA Global X Uranium ETF ........... Uranium Energy Corp.(UEC) is one of the lowest-cost producers of uranium in the United States. UEC's specialty is in-situ recovery (ISR), the most cost-efficient and environmentally friendly method of extracting uranium.
LTBR Lightbridge Corp... *CCJ(T/$15) .***URG(T/$1) ...UEC ...DNN ... URRE...FCUUF Fission Uranium...
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> SMH CandleGlance Semiconductor ...AMD,MVDA,CY,IDTI,IPHI,MPWR,MU,MXIM,TXN,LLTC .... RESN (T/$8) SEMI... AIXG (equip Germany) ... ACLS... Semiconductor equip. and materials... TSEM analog intensive mixed-signal semiconductor devices... CVV (equip) ...materials or coatings for aerospace engine components, medical implants, semiconductors, solar cells, smart glass, carbon nanotubes, nanowires, LEDs, MEMS, and other applications. LEDS... SemiLEDs Corporation develops, manufactures, and sells light emitting diode (LED) chips and LED components. Its products are used primarily for general lighting applications, including street lights, as well as commercial, industrial, and residential lighting; and specialty industrial applications, such as ultraviolet (UV) applications, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection....Taiwan. ***MU semiconductor systems ..... CY CypressSemi
SINO ...air delivery and frieght services
USDP ...Rail...oil...rail services
and oil/gas rail cars... big dividen...If oil continues to fall, it is likely that the return on investment for new pipelines will fall, leading to greater reliance on crude-by-rail. There remains a shortage of pipeline transportation for Canadian tar sands into the U.S. The oil sands are a better opportunity than U.S. shale plays as the asset life is significantly longer (30+ years). The exposure to Canadian oil sands makes it less sensitive to the vagaries of oil prices (see below added discussion about oil sands).
The value of rail over pipelines is relatively unknown by most investors. For one, the movement of oil by rail is cheaper than pipelines with lower fixed costs, and it's less capital-intensive. It is also readily scalable. Faster delivery than pipelines by two-thirds (<10 days v. 30 days) with flexibility to choose destination market once the train load is completed. https://seekingalpha.com/article/4081496-12-percent-yielder-niche-energy-space-9-straight-quarterly-distribution-hikes Shipping SEA CandleGlance Shipping TNK,EURN,TGP,NMM,SSW,SFL,TK,TNP, ... SEA vs. VALE http://marketrealist.com/2016/11/analyzing-crude-tanker-industry-week-46/ ***ANW (T/$6-8) shipping, LNG/LPG carriers a marine fuel logistics company markets supplies refined marine fuel and lubricants to vessels in port, at sea, rivers, worldwide .. ******ASC (T/$10) LNG/LPG carriers ...Ardmore Shipping Corporation, together with its subsidiaries, engages in the seaborne transportation of petroleum products and chemicals through product and chemical tankers worldwide. As of December 31, 2016, the company operated 27 vessels. It serves oil majors, oil companies, oil and chemical traders, and chemical companies. ***DCIX (T/$8) CONTAINER... **DHT (T/$5H, 6)(0.46bk) oil tankers...DLNG (T/$11) LIQUID NAT. GAS ***DRYS(T$2.53...1.64bk) dry bulk ... **DSX (T/$3H, 5) shipping... **EGLE...(T/$5) dry bulk... ***ESEA () dry bulk/containers... FRO (T/$6) ***GLBS (0.49bk)dry bulk,... ***GLBS (0.49bk)dry bulk,...
...(T/$23)Golar LNG Partners LP owns and operates floating storage regasification units (FSRUs) and liquefied natural gas (LNG) carriers under long-term charters in Brazil, the United Arab Emirates, Indonesia, and Kuwait. **GNK (T/$11H) dry bulk, company has 6.51share in cash...NNA **NMM (T/$2)... dry bulk... ***SALT dry bulk, has $3 a share in cash... SHIP() dry bulk...TOPS (0.34bk) oil tankers...**GASS crude oil and liquefied petroleum gas (LPG) ****SFL (T/$16) 11% dividend... fleet of 16 oil tankers, 22 dry bulk carriers, 20 container vessels, 2 car carriers, 2 jack-up drilling rigs, 2 ultra-deepwater drilling units, 5 offshore supply vessels, 2 chemical tankers, and 2 newbuilding oil pro duct tankers.
STNG (T/$8) Scorpio Tankers Inc., engages in the seaborne transportation of refined petroleum products worldwide. As of March 15, 2017, it owned 78 tankers comprising 22 LR2 tankers, 14 Handymax tankers, and 42 MR tankers with an average age of approximately 2.3 years; and 19 time chartered-in tankers, including 9 Handymax, 8 MR, 1 LR1, and 1 LR2 tankers.
***TK () crude oil and LNG carriers..company has $10.81 cash a share, Dividend% 3.20%
***** TNP (T/$6.50) ...Tsakos Energy Navigation Limited provides international seaborne crude oil and petroleum product transportation services worldwide. The company offers marine transportation services to national, major, and other independent oil companies and refiners under long, medium, and short-term charters. As of April 5, 2017, it operated a fleet of 62 double-hull vessels, including 57 conventional tankers, 2 liquefied natural gas carriers, and 3 suezmax DP2 shuttle tankers. Tsakos Energy Navigation Limited has a strategic partnership with Statoil for the crude oil tanker newbuildings. Other Stocks AMRS ...bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons. ATTO (T/$14) **AUO liquid crystal displays and other flat panel displays, solar and water re-cycling BKD ($T/16H) senior living ***BTE ...oil Eagle Ford... BRCD Brocade Commucations/Ruckus .. CCIH provider of Internet content and application delivery services and cloud in China... CELP (T/$8) oil gas equip. and services...
CHNR iron, zinc, and other nonferrous metals in the Peoples Republic of China CPSH ...produces and sells advanced material solutions to transportation, automotive, energy, computing/Internet, telecommunication, aerospace, defense, and oil and gas markets. Its products are used in applications that involve energy use or energy generation. The company primarily offers metal matrix composites that are a combination of metal and ceramic, such as baseplates for various applications, including motor controllers used in electric trains, subway cars, wind turbines, and hybrid and electric vehicles; baseplates and housings for use in radar, satellite, and avionics applications, as well as in modules built with wide band gap semiconductors; and lids and heatspreaders used with integrated circuits for use in Internet switches and routers. It also assembles housings and packages for hybrid circuits. CPS Technologies Corporation primarily sells its products to microelectronics systems companies in the United States *CRESY agriculture Argentina.. ESES oil/gas service FEYE
(T/$17-20) FireEye, Inc. provides cybersecurity solutions that allow organizations to prepare for, prevent, respond to, and remediate cyber-attacks. FPI (T/$10-12) ...Farmland Partners REIT...5% Div.
GLUU (T/$3.50) Games GARWF ()Golden Arrow Resources gold, silver, lead, zinc, and copper GRMX GSVC...venture capital pre-IPO IIN...(T/$11) body worn devices...micro-miniature electronics and hearing aids INFN (T/$12-13) INGN oxygen concentrators IPAS Telecom Services... .. JVA. Coffee... ***KTOS KTOS..(T/$7H-14-17) ... provides unmanned aerial, ground, seaborne, command, control, and communications systems. ****LKAI () mining/explores for gold, silver, lead, and zinc metals... *****LQMT () amorphous metal ( metallic glass/glassy metal) solid metallic material, usually an alloy, disordered atomic-scale structure. MTW farming machinery seasonal construction machinery seasonal ? NE (T/$7.50) ... ... NIOBF () niobium/scandium/titanium project located in Nebraska... NSSC
(T/$12) security softwar and devices...
*****OTIV (T/$3) On Track Innovations Ltd. is a developer of cashless payment solutions. The Company's segments include Retail and Mass Transit, Petroleum, Parking and Other. The Company offers solutions for banking, mobile network operators, vending, mass transit, petroleum and parking. The Company provides its customers with training and installation support, customer service and technical support. Its PayEnable technology can be implemented into a range of products. Its Retail and Mass Transit products include TRIO mPOS, Pico BT, WAVE, WAVE PKI, oti SATURN 6700 UNO, oti SATURN 6500 TRIO and oti SCI 6000. It also offers otiMetry and oti CONNECT 3000. Its EasyFuel Plus solution is a wireless, cashless, cardless and paperless refueling tracking and payment solution. Its EasyPark set of parking solutions provides parking fee collection, parking payment enforcement and parking management solution. Its MediSmart solution is an information management and claims submission system for the medical sector. PRTS (T/$5) online after market auto parts
RADA () military avionics systems, including flight data recorders for fighter aircraft; digital video/audio/data recorders with data transfer functions; high-rate data recorders for aircraft and airborne pods; video recorders and airborne data servers; a range of head-up-displays color video cameras for fighter aircraft; and various ground debriefing solutions. It also provides avionics solutions comprising integrated avionics upgrade suites for fighters and mission aircraft; mission and display computers; weapon management systems; data interface and processing computers; mission data recorders and debriefing solutions; HUD video cameras; and avionics for unmanned aircraft vehicles (UAVs). .ROX...sells beverage alcohol products in the United States and internationally RVLT (T/$16) Revolution Lighting Technologies, Light Emitting Diodes SFE venture capital...
SSKN (T/$12?) SVU (T/$5-6) wholesale and retail grocer...
**UAMY... produces and sells antimony, silver, gold, and zeolite products in the United States. The company's Antimony division offers antimony oxide that is primarily used in conjunction with a halogen to form a synergistic flame retardant system for plastics, rubber, fiberglass, textile good...
WPX... independent oil and natural gas exploration and production. (Google)***DMPID ... commercializing anti-cancer therapies ... ZNGA http://oracledispatch.com/ http://wealthyventurecapitalist.com/ Larger Cap.
(T/3.50) games...... FMCC Freddie Mac ... FNMA Fannie Mae
NUVA (T/$72H) NuVasive Medical Appliance/equip... UBNT (T/$60-66) Ubiquiti wireless equipment... ALGN (T/$110H) AlignMed. Appliance/equip dental...BOFI (T/$33) bank of internet Bofl Holdings savings and loan... ADRO (T/18) Biotech JUNO (T/29) Biotech... INFN (T/$13.50) Commctn Equip... UA (T/$30) Under Armour apparel clothing... ***SQ (T/$20h)Mobile payment services WDAY (T/$85H) Workday financial software cloud... PI (T/$40H) IMPINJ Commmunication equip...
http://stockcharts.com/public/3828047/tenpp/2 I long ago concluded that regression to the mean is the most powerful law in financial physics: Periods of above-average performance are inevitably followed by below-average returns, and bad times inevitably set the stage for surprisingly good performance.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 07/25/17 Word out of Japan today is that Toyota is working on launching a new solid-state battery for electric vehicles that will put it solidly in the EV game by 2022. Which leads to a simple question: What is a solid-state battery, and why does it matter? Back in February, John Goodenough observed, "Cost, safety, energy density, rates of charge and discharge and cycle life are critical for battery-driven cars to be more widely adopted." And risking a bad pun on his surname, he seemed to be implying that all of those characteristics weren't currently good enough in autos using lithium-ion batteries.
This comment is relevant because Goodenough, professor at the Cockrell School of Engineering at the University of Texas at Austin - it so happens, he turns 95 today - is the co-inventor of the lithium-ion battery, the type of battery that is pretty much the mainstay of current electric vehicles. And he and a research fellow at U of T were announcing they'd developed a solid-state battery, one that has improved energy density (which means a car so equipped can drive further) and can be recharged more quickly and more often (a.k.a., "long cycle life") than a lithium-ion battery. (Did you ever notice that with time your iPhone keeps less of a charge than it did back when it was shiny and new? That's because it has a limited cycle life. Which is one thing when you're talking about a phone. And something else entirely when it involves a whole car.) What's more, there is reduced mass for a solid-state battery. And there isn't the same safety concern that exists with li-ion batteries vis-à- vis conflagration (which is why at airplane boarding gates they say they'll check your carryon as long as you remove all lithium-ion batteries). Lithium-ion batteries may be far more advanced than the lead-acid batteries that are under the hood of essentially every car that wasn't built in Fremont, Calif., but as is the case with those heavy black rectangles, li-ion batteries contain a liquid. In the lithium-ion battery, the liquid, the electrolyte, moves the lithium ions from the negative to the positive side (anode to cathode) of the battery. In a solid-state design, there is no liquid sloshing around, which also means that there's no liquid that would freeze at low operating temperatures. What Toyota is using for its solid-state battery is still unknown, as is the case for the solid-state batteries that Hyundai is reportedly working on for its EVs. In the case of Goodenough's solid-state battery, sodium is used to form glass that serves as the electrolyte. Consider the implications of the development of solid-state batteries for powering cars and trucks versus using lithium-ion battery packs. For one thing, it will certainly mean that those Gigafactories that are sprouting up are going to have to undergo a significant change in what they're producing. And for another, it will more quickly bring EVs to price parity with internal combustion engine-powered vehicles. A recent UBS study estimated that parity would occur in 2023, but that finding was based on li-ion batteries; Toyota, Hyundai, and Prof. Goodenough could provide the proverbial game-changer. WKHS (T/$5) Workhorse Group Inc., a technology company, engages in the design, development, manufacture, and sale of electric medium duty trucks and unmanned aerial delivery systems that are integrated with electric vehicles. The company's products are used for commercial step vans in package delivery, product delivery, laundry and uniform service, food service, utility, and special use industries; medium duty buses, including para-transit, shuttle, and school buses; special use vehicles, such as emergency vehicles, wreckers, construction equipment, communications equipment, and military base application vehicles; and recreational vehicles. It also produces chassis with electric, propane, compressed natural gas, and hybrid configurations, as well as gasoline drive systems. The company was formerly known as AMP Holding Inc. and changed its name to Workhorse Group Inc. in April 2015.
Workhorse W-15 light duty platform design is an extension of the E-Gen electric technology used in Workhorse medium-duty delivery trucks, and is believed to be the first plug-in range-extended electric pickup built from the ground up by an original equipment manufacturer (OEM) in America
. With an expected 80-mile all-electric range using Panasonic 18650 Li-ion batteries
, the battery pack will cover the vast majority of miles driven in a day by fleet operators. If needed, the gasoline generator will initiate after battery power has been depleted, allowing additional range to complete the day's tasks. The W-15 will also feature the ability for utility fleets to power equipment directly from the vehicle's batteries, allowing a crew to complete their duties that require electricity without an external power source. With the goal of being the safest pickup truck in America for fleet operators, the W-15's safety features include an extra large crumple zone and lower center of gravity while still providing ground clearance. The W-15 also offers crash mitigation technologies, including automatic braking and lane centering. Once production commences, the W-15 is anticipated to have a $52,500 MSRP. After 78 years, the helicopter has been reinvented - SureFly personal helicopter KNDI...China electric vehicle...at one time this stock traded above $20...now 2017 there are a ton of law suits after Kandi Technologies ass.
With the subsidy-payment drama now behind the company, its focus will be on developing new vehicles that won't rely solely on subsidy payments to be economically viable. Kandi is currently developing those EV products for after 2020, when the subsidy payments end. The company also has its hands full launching two new EV models this year and preparing its car-making joint venture company for its initial public offering.
This will be a pivotal year for Kandi and its investors. But don't expect its stock price to regain its lost value until management proves it can take steps to reduce its reliance on subsidy payments while reigniting its revenue.
Daniel Miller has no position in any stocks mentioned. The Motley Fool An Electric Car Vending Machine Four-Passenger Pure Electric Sedan Vehicle
On 22 August 2016. Kandi Technologies Group, Inc. (NASDAQ:KNDI) announced that Kandi Electric Vehicles Group Co., Ltd. (the “JV Company,” a 50/50 joint venture between Kandi and Geely Automobile Holdings Ltd.) has unveiled its new pure electric vehicle (“EV”) model named the “Global Hawk K21.” This new all-electric sedan is equipped with automatic braking technology, a voice control system, a infotainment system, remote software update capabilities, and a fully-integrated electrical control system. Packaged with the ternary battery, the vehicle has a top speed of 100+ km/h and a driving range exceeding 150km on a single full charge. The Global Hawk K21 joins the ranks of mid-tier luxury pure electric vehicles offered by the JV Company.
Marijuana Stocks http://cannabisstocksnews.com/ http://www.fool.com/investing/2016/05/27/is-big-government-about-to-make-big-green-on-marij.aspx Marijuana Stocks The HYPE will suck you in...so be careful... http://www.buyupside.com/sample_portfolios/cannabisallwithprices.php Database of Marijuana (Cannabis) Stocks
--- Database of Marijuana (Cannabis) Stocks
Beginning in 2014, marijuana stocks were in vogue. Investors were scrambling the markets to find almost any stock that promoted themselves as an emerging player in the cannabis industry. The drawback in that investment strategy, however, was that many investors were too preoccupied with finding a company with a catchy name, rather than a company that actually had some substance
. While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant's cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions
. With that said, if investors had only remained diligent on seeking realistic and lucrative potential through cannabis pharmaceuticals, Vitality Biopharma (OTCQB:VBIO
) would not have been overlooked. In fact, VBIO is one of only three cannabinoid related companies that I see as actually being able to produce any meaningful revenue within the next few years. Investors need to separate themselves from the nonsense being promoted by companies that are looking to cultivate and sell the product. Despite what they say, once Big Tobacco decides that it's time to enter the market, these small time entrepreneurial bud houses will be pushed out of business faster than a bee to a beetle. For those investors betting a small fortune on any of these penny stock names, consider saving your money while you still can. The real money will be made in cannabinoid pharmaceuticals (CP) https://seekingalpha.com/article/4031914-vitality-biopharma-seriously-undervalued-cannabis-stockhttp://www.fool.com/investing/2016/05/27/is-big-government-about-to-make-big-green-on-marij.aspx
Marijuana Stock Scams Inside The Pot Stock Bubble
There's no two ways about it: As an investor, you'd struggle to find an industry with a more appetizing long-term growth rate than legal marijuana. According to cannabis research firm ArcView, North American legal sales increased by 34%, to $6.9 billion in 2016, albeit black-market sales still totaled $46.4 billion. As more U.S. states push to legalize, and with Canada potentially on the precipice of legalization by 2018, the expectation is more that this $46 billion-plus in illicit sales will shift to the legal and regulated markets in the years to come.
By 2026, investment firm Cowen & Co. anticipates total legal sales could reach $50 billion. If that's the case, we're talking about more than 23% annual growth for a decade. It's these figures that are attracting businesses and investors to marijuana stocks in droves. HMMJ.TO Medical Marijauna Life Science ETF Medical Marijuana ***ACBFF (T/$ 3.25) AURORA CANNABIS is one of the leading players in the raging Canadian cannabis space. We have been strong fans of ACBFF over the past year because of its topline growth and fortress balance sheet – nearly $120M in cash against basically no current liabilities. licensed producer of medical marijuana pursuant to the Marijuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada.
APH.TO Aphria Inc is engaged in the production and selling of medicinal marijuana, and while the stock has trended downward since April, the constant profits here suggest there is a lot of upside. The recent pro-marijuana legislation from the Canadian government is sure to boost companies with the reputation of Aphria Inc.Aphria’s $137 million expansion project is well underway to ramp up output to 70,000 kg. If Aphria successfully ramps up production, we believe its share price could go much higher. GBLX
() Growblox Sciences is a biotechnology research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
On may 23 GBLX announced the filing of its latest patent application by its wholly-owned subsidiary, Growblox Life Sciences, LLC for the treatment of chronic pain and heart therapies based on myrcene-containing complex mixtures (“MCCM”). The current US opioid epidemic, along with growing public and government concern regarding opioid abuse, makes new pain treatments a promising field of research and development. Our novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol (“THC”), which minimizes their potential for abuse. Pain management represents an estimated health burden of between $560 to $650 billion dollars for chronic pain and between $17 to $20 billion dollars for immunological/neuropathic pain in the US alone. In addition, our novel heart disease formulations address the $316 billion dollar heart therapy market in the US. http://www.microcapdaily.com/long-and-short-on-growblox-sciences-inc-otcmktsgblx/118916/ GWPH GW Pharmaceuticals ... developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. CAMBRIDGE U.K. *****CARA
(T/$21-32) chronic pain ...Cara's ties to cannabis relates to its preclinical research involving CR701, a cannabinoid receptor agonist that's designed to treat chronic pain. Considering that there were no documented overdose-related deaths from marijuana in 2016, compared to over 20,000 prescription opioid overdose deaths in 2015, there's a clear push to consider CB agonists as a possible solution to chronic pain. In rodent models, CR701 produced "hyperalgesia (sensitization of nerve ending to panful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions." ****CRBP (T/17-24) Corbus Pharmaceuticals
is considerably more of a wildcard than GW Pharmaceuticals, but if one specific clinical trial goes its way, it could easily leap to $1 billion in annual sales. Corbus' pipeline consists of a solitary drug known as anabasum, which is a synthetic oral endocannabinoid-mimetic drug that binds to the CB2 receptors expressed on immune cells and fibroblasts. Its drug is being tested in four indications, but one stands out head and shoulders above the rest: cystic fibrosis (CF). There are few drugs to treat CF, and most that are FDA approved target a very specific mutation, making their impact limited within the CF community. Anabasum is believed to have a global anti-inflammatory effect, meaning it could be taken by most, or all, CF patients.The downside? Even though anabasum hit its primary endpoint of a 75% reduction in the pulmonary exacerbation event rate in phase 2 trials, it didn't provide any improvement in lung function as measured by the forced expiratory volume within the first second (FEV1) test. FEV1 improvement is often seen with FDA approved CF drugs, leaving anabasum's impact on CF somewhat uncertain.
(Motley Fool) ERBB (Google) American Green is heavily banking on the Arizona marijuana market. ERBB signed a Purchase Agreement for a Class A building in Tempe, Arizona that will be a prime location for a Medical Marijuana Dispensary it will lease to one of its license holder clients. IGC cannabinoid based biopharmaceutical for end of life supportive care,India... ****INSY ...(T-$16-22) Insys ...MEDICAL MARIJUANA, synthesized marijuana cannabidiol...*** 06/16/2017 Insys has been the subject of negative publicity as state and federal investigations continue against six ex-employees regarding the sales and billing practices of the company in the past. The investigations surround the company's drug, Subsys, a fentanyl-based sublingual spray used for the treatment of cancer patients. Insys issued a response to recent media reports by reiterating its commitment towards the highest ethical standards and compliance with all its activities and business practices and complying with governing laws and regulations and cooperating with relevant governmental authorities in ongoing investigations. Management also highlighted that Insys intends to play a meaningful role in providing solutions to address the opioid epidemic by developing innovative products. These potential product solutions include cannabidiol (a novel, non-opioid) for the treatment of opioid dependence, for the treatment of pain and naloxone nasal spray for the treatment of opioid overdose.Recent negative headlines continue to impinge the business risk profile & brand image of the company. Elizabeth Gurrieri, a former manager of reimbursement services for Arizona-based Insys, will plead guilty to one count of wire fraud conspiracy, prosecutors said in a letter filed in Boston federal court. The filing is part of the criminal case against six ex-Insys executives and managers including former Chief Executive Michael Babich, who, prosecutors say, participated in a scheme to bribe doctors to prescribe the drug, Subsys. Gurrieri would become the second former Insys employee nationally to plead guilty in connection with Subsys, an under-the-tongue spray containing fentanyl, a highly addictive and regulated synthetic opioid. On the brighter side, FDA approved the final labeling for Syndros (dronabinol oral solution, a pharmaceutical version of THC), which may classify the drug as a Schedule II controlled substance. Insys expects to launch the product in August 2017. Syndros is indicated for the treatment of anorexia associated with weight loss in patients with AIDS and in the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros will be a direct competitor to Marinol, a product offered by Abbvie in pill form. Since Syndros is a liquid, it should be easier to swallow and can be administered in prescribed dosages. Dronabinol was approved by the FDA decades ago as a treatment option for cancer patients. Today, the potential applications for dronabinol, including sleep apnea and opioid dependency, could catapult this drug to annual sales in the billions. LBUY
LEAF.TO As a licensed producer of cannabis-based pharmaceutical products, MedReleaf Corp has a head start on the coming boom in Canada. Early July has seen a bounce in the stock price, and investors may look to ride it upward from here. Med Releaf could become Canada’s second biggest medical marijuana company after Canopy Growth Cooperation as many analysts expect the ‘legal weed’ industry to grow 25 percent on an annual basis over the next 10 years. MedReleaf has seen its share price fall since June, but has steadied out in recent months and could be poised for gains as the expected legalization of recreational marijuana materializes. MJNA MORE HYPE THAN FACTS don't trade ...medical marijuana and industrial hemp...Medical Marijuana Inc (OTCMKTS:MJNA), according to company documents, bills itself as an investment holding company that operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high-value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries.
PRMCF Cronos ...google .. 7% of HMMJ.TO ETF
OGRMF google TRPX () ... Therapix Biosciences Ltd is a biopharmaceutical Israeli-based company engaged in identifying and investing in biopharma technologies and developing approved drugs based on cannabinoid molecules. Phase 3 trial Tourette's syndrome, a somewhat bizarre disorder that has become something of a counterculture icon of a disease. Sufferers often have uncontrollable tics, which might include twitching, shouting profanity or other sounds, eye blinking, coughing and throat clearing. It's actually a surprisingly common neurological condition. Studies suggest that the prevalence of Tourette’s in the overall population at any time is 0.1% for impairing cases and 0.6% for all cases. ***TWMJF Canopy Growth Corp. a producer and retailer of medical cannabis products and oils in Canada
VBIO ... https://seekingalpha.com/article/4031914-vitality-biopharma-seriously-undervalued-cannabis-stock
VBIO is intensely focused on treating Narcotic Bowel Syndrome (NBS) and Inflammatory Bowel Disease (IBD). In the case of NBS, it's been reported that up to 81% of opiate users have functional bowel disorders, with more than 58% reporting chronic abdominal pain during an independently conducted study. From this set of patients, over 6% will ultimately develop NBS. The symptoms associated with NBS can be devastating, and it has been reported that the downward spiral related to quality of life issues has been associated with 61% of all drug overdose deaths. In prior, non-related studies, cannabinoids have proven the ability to effectively treat Crohn's disease patients, with over 40% of the patients having had the disease put into remission. These prior results, though unrelated to Vitality Biopharma, do have the potential to open additional regulatory pathways for expedited approval. VBIO product pipeline includes Cannabosides – VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides – VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease.
??? A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
On March 10 VBIO announced it has obtained positive results demonstrating antimicrobial activity of cannabinoids and filed for patent protection on the use of cannabinoid compounds for the treatment of microbes including Clostridium difficile and other “superbug” pathogens. Utilizing a list of the top drug-resistant pathogens from the United States Centers for Disease Control and Prevention (CDC), Vitality researchers screened for antimicrobial activity in their portfolio of compounds. Vitality Biopharma discovered new antimicrobial activities for cannabinoids, and as a result has filed for patent protection on the use of cannabinoids and cannabinoid prodrugs for the treatment of multiple pathogenic bacterial infections.
Vitality Biopharma Inc(OTCMKTS:VBIO) says it is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. VBIO product pipeline includes Cannabosides – VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides – VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease.
Vitality Biopharma has developed a new class of cannabinoid prodrug, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. http://www.microcapdaily.com/the-gloves-come-off-on-vitality-biopharma-incotcmktsvbio/119372/ Other Marijuana ***AMMJ two divisions within the regulated cannabis industry: consulting and professional services, and the sale of products and equipment utilized in the cultivation, processing, transportation or retail sale of cannabis. The Company offers consulting services for companies associated with the cannabis industry in various stages of development. Its service offerings include Cannabis Business Planning, Cannabis Business License Applications, Cultivation Build-out Oversight Services, Cannabis Regulatory Compliance, Compliance Audit Services, Cannabis Business Growth Strategies and Cannabis Business Monitoring. Its Equipment and Supplies product offerings include The Satchel, SoHum Living Soil, High Density Racking System and The Cultivation Cube. ****APHQF Aphria (NASDAQOTH:APHQF). Aphria has the distinction of being the most prominently profitable marijuana stock, with the company reporting five consecutive quarterly profits. *** CANN General Cannabis... GRNH GreenGro greenhouse/growing equiptment.. ***HEMP marijuana industries... Perhaps no other name has personified the pot stock boom and bust more so than Hemp Inc (OTCMKTS:HEMP) CEO Bruce Perlowin. He relished his role as the “King of Pot” and touted his background as a former drug smuggler who served nine years in prison. Well, it seems he never outgrew his old ways as the SEC charged Hemp Inc, Bruce Perlowin, and others with a “long-running and profitable scheme resulted in the sale of hundreds of millions of unregistered and purportedly unrestricted Hemp shares to public investors. The execution of this scheme involved, among other things, purported gifts and consulting agreements that do not appear to have been bona fide and fraudulent statements made to Commission-registered broker-dealers.” June 22, 2016 The sad part is that Hemp was actually making some progress. Last month and after months of waiting, Hemp Inc finally produced its first environmentally friendly product-to-market from the company’s new decortication plant in Spring Hope, North Carolina. This was a pretty big deal for HEMP and its investors as the company has basically bet the ranch on this plant and the state of North Carolina. We told investors back in February that the company was making a comeback and things were finally starting to come together.
ZYNE (T/$7) 08/07 failed trial for epilepsy...Zynerba Pharmaceuticals are also working on extracting the benefits of cannabis in order to address targeted medical applications. hareholders are eagerly awaiting the release of phase 2 data from two key studies – Star 1, which is examining ZYN002 in adults with epilepsy, and Stop, which also involves ZYN002 as a treatment for patients with osteoarthritis. Zynerba noted that it was to report data on both studies in either July or August, which essentially means a data release is imminent. Considering how little we have in the way of efficacy data on ZYN002, these two studies are expected to give us our first real look at what ZYN002 can do, and whether Zynerba's drug platform has merit.
LBUY () Leaf Buyer ...hyped as the Priceline of pot...(theStreet.com) VNNYF... VPRB... UBQU... MCIG... INSY... CARA ...APHQF... *DIGP cannabis testing; and provides cannabis news with a news/talk radio, ... *VRTHF...medical marijuana...CBDS...Cannabis Sativa... HMPQ Hemp America...
...T-$22 MEDICAL MARIJUANA, synthesized marijuana cannabidiol... *VRTHF...medical marijuana...CBDS...Cannabis Sativa... HMPQ Hemp America...
ERBB, CBIS,PHOT...VBIO... **HTCO... TRLFF...***TWMJF http://stockcharts.com/c-sc/sc?s=GWPH&p=D&yr=0&mn=6&dy=0&i=p40394851540&r=1398788554470
WHO CAN BE A MEDICAL PATIENT IN WASHINGTON? WHO CAN PURCHASE RECREATIONALLY? Under Washington law, recreational marijuana can be purchased, sold, or transferred by and to anyone 21 years and older. Washington medical patients first must be Washington state residents. Patients are not restricted by age, though in order for someone under 18 to become a medical patient, the parent must consent and register to be the child's caregiver. The physician is required to consult with other physicians before certifying the medical use of marijuana for patients under 18. Furthermore, the physician must see the patient at least twice a year - as opposed to the annual requirement for adults - to evaluate the patient symptoms and effectiveness of treatment.
For all other Washington medical patients, you must be at least 18 years of age. The state of Washington currently recognizes the following ailments and debilitating illnesses in their medical program:
The Cannabis Patient Protection Act also allows petitions for additional conditions and diseases to be added to the list of approved illnesses. Anxiety, depression, and a variety of other mental health issues, however, have been determined by Washington state not to be adequately addressed by medical marijuana.
Human Immunodeficiency Virus (HIV)
Epilepsy or other seizure/ spasticity related disorders
Pain not adequately addressed by current medicine options
Glaucoma, either acute or chronic, that is unresponsive to current treatments
Anorexia, which can result in nausea, vomiting, wasting, appetite loss, cramping, seizures, muscle spasms, or spasticity
Chronic kidney failure
Posttraumatic stress disorder (PTSD)
Traumatic brain injuries
HOW DO I BECOME A MEDICAL MEMBER IN WASHINGTON? First, you must be a Washington state resident. The next step is seeking a recommendation from a doctor in good standing with the state. Washington currently recognizes the following health professionals as being eligible to recommend patients:
- Medical doctor (MD)
Physician assistant (PA)
Osteopathic physician (DO)
Osteopathic physician assistant (DOA)
Advanced registered nurse practitioner (ARNP)
These are ten of Bob Farrell’s most famous observations: Linda Raschke's 12 Rules for Technical Trading. 1. Buy the first pullback after a new high. Sell the first rally after a new low.
1. “Markets tend to return to the mean over time.” For those of you who’ve taken statistics, you know exactly what this refers to: stocks often move too far in one direction as euphoria or pessimism clouds people’s thinking. Investors lose perspective and start believing the little devil on their shoulders.
2. “Excesses in one direction will lead to an opposite excess in the other direction.” I think of it like bungee jumpers whose cords stretch out and then compress multiple times before they come to rest or achieve equilibrium.
3. “There are no new eras – excesses are never permanent.” As the latest hot sector climbs higher and higher, you inevitably hear variations of the chorus shouting “it’s different this time”. Of course, human nature does not change so it never really turns out to be any different.
4. “Exponential rapidly rising or falling markets usually go further than you think, but they do not correct by going sideways.” The smart money locks in profits which leads to significant selling and inevitably to a correction.
5.“The public buys the most at the top and the least at the bottom.” It’s been this way since humans invented commerce.
6.“Fear and greed are stronger than long-term resolve.” Research in behavioral finance has shown that stock market gains make us exuberant; they enhance well-being and promote optimism which makes investors like to buy. Losses, on the other hand, bring sadness, disgust, fear and regret. Fear increases the sense of risk which thereby makes investors shun stocks.
7.“Markets are strongest when they are broad and weakest when they narrow to a handful of equities.” Think of it as strength in numbers. Broad breadth (i.e. market participation) and big volume is important. When wide ranging momentum channels into a small number of stocks, the top is near.
8.“Bear markets have three stages – sharp down move, reflexive rebound and a drawn-out fundamental downtrend.”
9.“When all the experts and forecasts agree, something else is going to happen.” Farrell suggests that patient buyers who raise cash in frothy markets and reinvest when sentiment is darkest can profit nicely.
10.“Bull markets are more fun than bear markets.” It has been my observation that historically the markets have rewarded optimists to a far larger degree than pessimists. I prefer to play in the bulls’ camp.
Trade well; trade with discipline!-- Gatis Roze
2. Afternoon strength or weakness should have follow through the next day.
3. The best trading reversals occur in the morning, not the afternoon.
4. The larger the market gaps, the greater the odds of continuation and a trend.
5. The way the market trades around the previous day’s high or low is a good indicator of the market’s technical strength or weakness.
6. The previous day’s high and low are two very important “pivot” points, for this was the definitive point where buyers or sellers came in the day before. Look for the market to either test and reverse off these points, or push through and show signs of continuation.
7. The last hour often tells the truth about how strong a trend truly is. “Smart” money shows their hand in the last hour, continuing to mark positions in their favor. As long as a market is having consecutive strong closes, look for up-trend to continue. The up trend is most likely to end when there is a morning rally first, followed by a weak close.
8. High volume on the close implies continuation the next morning in the direction of the last half-hour. In a strongly trending market, look for resumption of the trend in the last hour.
9. The first hour’s range establishes the framework for the rest of the trading day.
10. A greater percentage of the day’s range occurs in the first hour then was the case in the past, and thus it has become increasingly important to trade aggressively if there are early signs of a strong trend for the day.
11. There are four basic principles of price behavior which have held up over time. Confidence that a type of price action is a true principle is what allows a trader to develop a systematic approach. The following four principles can be modeled and quantified and hold true for all time frames, all markets. The majority of patterns or systems that have a demonstrable edge are based on one of these four enduring principles of price behavior. Charles Dow was one of the first to touch on them in his writings.
Principle One: A Trend Has a Higher Probability of Continuation than Reversal
Principle Two: Momentum Precedes Price
Principle Three: Trends End in a Climax
Principle Four: The Market Alternates between Range Expansion and Range Contraction!
12. In the world of money, which is a world shaped by human behavior, nobody has the foggiest notion of what will happen in the future. Mark that word – Nobody! Thus the successful trader does not base moves on what supposedly will happen but reacts instead to what does happen. To better understand and appreciate the trading systems seen on this board Break a bad habit "The truth is that trading, both successful and unsuccessful, is more about psychology than tactics." - Jack Schwager Multicollinearity... Bollinger Bands... CCI... NOISE...RANDOM...CHAOS...ORDER...STRUCTURE ...if you don't know where you are at...how will you know where you're going? Structure= creates Order out of CHAOS Keep Keeping It Simple...Buy low...Sell high...relative to what...? (one day will edit) Patience...Moving averages...CONFLUENCE..
3day moving average study...Grail QUESTion
...it may cure that gambler in you...with understanding ...gambling/fear gets replaced with confidence and patience... http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78642915 SLV...3 cross 5 moving average Adapting Moving Averages to Market Action Quest of the TREND Definition for TREND...and...Momentum Volume speaks VOLUMES... Momentum volume and momentum Stochastics Accumulation/Distribution and how to use the Candle Glance Charts
Price gaps occur when the range of a price bar does not include the range of the previous bar. It acts as a reliable level of support and resistance for subsequent price action and should always be monitored. Does Momentum Investing Work? Momentum Investing With ETFs !PMOBUYALL...Percentage of PMO Crossover Buy Signals Sentiment Extreme Gold Silver www.vectorgrader.com $VIX... "Black Swan"
Hot IPO Pullback Rules (via 'Hit & Run Trading II'): Our proven model does not conclusively show that (any stock) will beat estimates this quarter. That is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.